

1 **Clinical Practice Guideline:** **Biofeedback**
 2
 3 **Date of Implementation:** **November 15, 2018**
 4
 5 **Product:** **Specialty**
 6

7 **Table of Contents**

8 GUIDELINES 2
 9 Medically Necessary 2
 10 Unproven 3
 11 BACKGROUND 4
 12 Urinary Incontinence 6
 13 Fecal Incontinence 8
 14 Levator Ani Syndrome 8
 15 Chronic Constipation 8
 16 Migraine and Tension-type Headache 9
 17 Neuromuscular Rehabilitation10
 18 EVIDENCE REVIEW10
 19 Urinary Incontinence10
 20 Fecal Incontinence17
 21 Levator Ani Syndrome20
 22 Chronic Constipation21
 23 Migraine and Tension-type Headache23
 24 Neuromuscular Rehabilitation24
 25 Other Conditions29
 26 Cancer29
 27 Chronic Neck, Upper Back and Low Back Pain29
 28 Epilepsy31
 29 Fibromyalgia32
 30 Functional Dyspepsia (FD)32
 31 Hypertension33
 32 Irritable Bowel Syndrome (IBS)35
 33 Labor Pain35
 34 Knee Conditions35
 35 Nonneuropathic Voiding Disorders37

1 Raynaud’s Syndrome.....37
 2 Recurrent Urinary Tract Infection38
 3 Rheumatoid Arthritis (RA).....38
 4 Sleep Bruxism39
 5 Temporomandibular Disorders (TMD)/Temporomandibular Joint (TMJ) Disorders39
 6 Tinnitus.....40
 7 Upper Limb Pain41
 8 Vulvodynia41
 9 EEG Biofeedback/Neurofeedback.....42
 10 Home Biofeedback Devices47
 11 PRACTITIONER SCOPE AND TRAINING49
 12 References49

13
 14 **GUIDELINES**

15
 16 **Medically Necessary**

17 Biofeedback performed by a licensed healthcare professional is considered medically
 18 necessary for **ANY** of the following conditions*:

- 19 • Chronic constipation with dyssynergic defecation (adults only).
- 20 • Fecal incontinence for patients with:
 - 21 ○ Some degree of rectal sensation; and
 - 22 ○ Ability to contract the sphincter voluntarily; and
 - 23 ○ Failure/intolerance/contraindication of treatment with dietary changes,
 - 24 devices, or drugs.
- 25 • Stress, urgency, mixed, or overflow urinary incontinence when there is
 26 failure/intolerance/contraindication of other nonpharmacologic treatment (e.g.,
 27 bladder training and/or pelvic floor muscle training [PFMT]) (children and adults)
- 28 • Migraine and tension headaches (children and adults).
- 29 • Muscle re-education of specific muscle groups or for treating pathological muscle
 30 abnormalities of spasticity, incapacitating muscle spasm, or weakness, and more
 31 conventional treatments (heat, cold, massage, exercise, support) have not been
 32 successful.
 - 33 ○ This therapy is not covered as medically necessary for treatment of ordinary
 34 muscle tension states or for psychosomatic conditions.
- 35 • Refractory levator ani syndrome (e.g., proctalgia fugax, chronic anal pain
 36 syndrome, anal spasm) with dyssynergic defecation when:
 - 37 ○ Condition is not neurological, or disease based.
 - 38 ○ Failure/intolerance/contraindication of conservative treatment including:
 - 39 ▪ High-fiber diet;

- 1 ▪ Withdrawal of drugs that cause constipation (e.g., calcium channel
- 2 blockers, narcotics) or diarrhea (e.g., antibiotics, quinidine, theophylline);
- 3 ▪ Perineal strengthening exercises;
- 4 ▪ Rectal massage;
- 5 ▪ Warm baths; and
- 6 ▪ Drug therapy (e.g., muscle relaxants, non-narcotic analgesics, and
- 7 sedatives).

8 *NOTES:

- 9 • Patients must be cognitively intact and willing and motivated to learn and practice
- 10 the specific tasks needed to correct/improve their condition.
- 11 • The patient’s care plan requires co-management with other appropriate health care
- 12 providers.
- 13 • There should be a written treatment plan which must include **all of** the following
- 14 information:
 - 15 ○ The specific diagnosis/conditions to be treated;
 - 16 ○ Long- and short-term goals;
 - 17 ○ Measurable objectives;
 - 18 ○ The time frame and the frequency of treatment in which the goals and objectives
 - 19 will be achieved.

21 **Unproven**

22 Biofeedback for **ANY** other indication is considered unproven, including but not limited

23 to:

- 24 • As a rehabilitation modality for spasmodic torticollis, spinal cord injury, or
- 25 following knee surgeries
- 26 • Attention deficit hyperactivity disorder (ADHD)
- 27 • Autism
- 28 • Bell's palsy (idiopathic facial paralysis)
- 29 • Cardiovascular diseases (e.g., heart failure)
- 30 • Chemotherapy-induced peripheral neuropathy
- 31 • Childhood apraxia of speech
- 32 • Chronic fatigue syndrome
- 33 • Chronic pain (e.g., back pain, fibromyalgia, neck pain) other than migraine and
- 34 tension headache
- 35 • Epilepsy
- 36 • Essential hypertension (e.g., by means of the RESPeRATE™ Device)
- 37 • Facial pain
- 38 • Functional dysphonia
- 39 • Home Biofeedback (for any indication)
- 40 • Improvement of anorectal/bowel functions after sphincter-saving surgery for rectal
- 41 cancer

- 1 • Neurogenic bladder
- 2 • Non-neuropathic voiding disorders
- 3 • Labor pain
- 4 • Prophylaxis of medication overuse headache and pediatric migraine
- 5 • Raynaud's disease/phenomenon
- 6 • Rheumatoid arthritis
- 7 • Sleep bruxism
- 8 • Spasticity secondary to cerebral palsy
- 9 • Temporomandibular joint (TMJ) syndrome
- 10 • Toe-out gait modification/retraining in people with knee osteoarthritis
- 11 • Vaginismus
- 12 • Vulvodynia

13
14 The following is considered not medically necessary and/or unproven:

- 15 • Electroencephalography (EEG) biofeedback or neurofeedback for any indication

16
17 **Covered When Medically Necessary**

CPT® Codes	CPT® Code Description
90901	Biofeedback training by any modality
90912	Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; initial 15 minutes of one-on-one physician or other qualified health care professional contact with the patient
90913	Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; each additional 15 minutes of one-on-one physician or other qualified health care professional contact with the patient (List separately in addition to code for primary procedure)

18
19 **BACKGROUND**

20 The three most commonly used forms of biofeedback therapy are: (1) electromyography
21 (EMG), which measures muscle tension; (2) thermal biofeedback, which measures skin
22 temperature; and (3) neurofeedback or electroencephalography (EEG), which measures
23 brain wave activity. Various forms of biofeedback appear to be effective for a narrow
24 range of health problems. This guideline includes various indications or proposed
25 indications for biofeedback (EMG and/or thermal), electroencephalography (EEG)
26 biofeedback or neurofeedback, and in-home biofeedback devices.

1 Biofeedback therapy provides visual, auditory, or other evidence of the status of certain
2 body functions so that a person can exert voluntary control over the functions, and thereby
3 alleviate an abnormal bodily condition. Biofeedback therapy often uses electrical devices
4 to transform bodily signals indicative of such functions as heart rate, blood pressure, skin
5 temperature, salivation, peripheral vasomotor activity, and gross muscle tone into a tone or
6 light, the loudness or brightness of which shows the extent of activity in the function being
7 measured. It emphasizes relaxation, enhancement of muscle contraction and/or stress-
8 reduction. Biofeedback is considered an alternative medicine technique (National Center
9 for Complementary and Alternative Medicine [NCCAM], 2017; Holroyd et al., 2003;
10 Karmody, 2003; Kiresuk et al., 2005).

11
12 There are several different types of biofeedback. The biofeedback modality selected for
13 therapy depends on the condition to be treated. EMG biofeedback measures muscle tension
14 and is proposed for the treatment of chronic muscle stiffness, injury, and pain (e.g., neck
15 and back pain); headaches, asthma, incontinence; and intestinal symptoms. Thermal or
16 temperature biofeedback measures skin temperature and is proposed for the treatment of
17 circulatory disorders, such as headaches, hypertension, and Raynaud’s phenomenon.
18 Galvanic skin response (GSR) biofeedback, also called electrodermal response (EDR),
19 electrodermal activity (EDA), skin conductance response (SCR) or skin conductance level
20 (SCL) biofeedback, measures electrical conductance in the skin associated with sweat
21 gland activity and perspiration. GSR is proposed for the treatment of anxiety disorders and
22 phobias. Another form of biofeedback is electroencephalogram (EEG) biofeedback, also
23 called neurofeedback, brainwave biofeedback or neurotherapy, which measures alpha
24 (associated with relaxation and meditation) and theta (associated with focused attention)
25 brainwave activity. It is proposed to counterbalance genetic and environmental tendencies
26 by learning to alter brain wave patterns. EEG biofeedback has been proposed for the
27 treatment of multiple conditions including insomnia, attention deficit hyperactivity
28 disorder (ADHD), dyslexia, anxiety disorders, autism spectrum disorders, epilepsy,
29 addictions, tinnitus, brain injury, depression, learning disabilities, pervasive developmental
30 delay/intellectual disability, fibromyalgia, dyslexia. However, the evidence in the
31 published peer-reviewed scientific literature does not support the efficacy of EEG
32 biofeedback.

33
34 Forms of biofeedback have been in use in physical therapy for more than 50 years, where
35 it is beneficial in the management of neuromuscular disorders. Biofeedback techniques
36 have shown benefit when used as part of a physical therapy program for people with motor
37 weakness or dysfunction after stroke, after orthopedic surgery, or due to other
38 neuromuscular diseases. These methods are getting better at training for complex task-
39 oriented activities like walking and grasping objects as technology continues to advance.
40 Aside from neuromuscular retraining, the most common use for biofeedback is to help with
41 chronic symptom management due to anxiety, pain, and urinary and fecal incontinence.
42 These techniques focus on managing the overactive sympathetic response and coordinating

1 muscle activity in gastrointestinal and genitourinary tracts. Biofeedback techniques are
2 generally regarded as safe and free of side effects. For this reason, they are incorporated
3 into treatment plans despite lacking strong evidence to support their benefits (Malik and
4 Dua, 2021).

5
6 Although there are numerous biofeedback devices available for home use, biofeedback
7 should be performed in a clinical setting with the continuous presence of the physician or
8 by a qualified non-physician practitioner. Continuous presence requires one-on-one face-
9 to-face involvement with the patient and practitioner during training. Qualified non-
10 physician practitioners include physical and occupational therapists in independent
11 practice, Nurse Practitioners, Physician Assistants, and Clinical Nurse Specialists.
12 Examples of home devices include: StressEraser® (Helicor, Inc., New York, NY) for mind
13 and body relaxation; BrainMaster (BrainMaster Technologies, Inc., Oakwood Village,
14 OH) EEG biofeedback devices; GSR/Temp2XTM (Biofeedback Instrument Corp., New
15 York, NY) temperature biofeedback system; and RESPeRate (Intercure Ltd., Lod, Israel)
16 which uses therapeutic paced breathing to lower blood pressure.

17 **Urinary Incontinence**

18 Urinary incontinence (UI) affects people of all ages, especially elderly women. Among
19 adults, there are 4 prevalent types of UI: stress incontinence (closure problem), urge
20 incontinence (storage problem), overflow incontinence, and mixed stress and urge
21 incontinence. In women, stress incontinence is generally caused by an incompetent urethral
22 mechanism which arises from damage to the sphincter(s) or weakening of the bladder neck
23 support that typically occurred during childbirth. In men, stress incontinence is usually a
24 consequence of operations for benign prostatic hypertrophy (BPH) or prostate cancer. Urge
25 incontinence is usually associated with an over-activity of the detrusor muscle. When the
26 involuntary contraction of the detrusor muscle is associated with a neurological deficit, it
27 is known as detrusor hyperreflexia. On the other hand, when detrusor over-activity is not
28 associated with any neurological deficit, it is labeled as detrusor instability (unstable
29 bladder). Overflow incontinence may be due to an underactive detrusor muscle or
30 obstruction of the urethra. In men, overflow incontinence associated with obstruction is
31 usually due to prostatic hyperplasia. Urethral obstruction in women may occur as a
32 consequence of anti-incontinence operation or severe prolapse of the uterus or relaxation
33 of the anterior vaginal wall with cystocele or cystourethrocele.
34

35
36 Over 20 million women experience stress, urgency, or mixed incontinence (Wu et al.,
37 2009). There are limited non-surgical treatment options available for women with stress,
38 mixed, and urgency UI and most require the involvement of skilled healthcare
39 professionals, which may be limited in number. Additionally, geographical access can be
40 challenging for first line treatment of UI. Studies estimate that at least 50% of women do
41 not seek care for UI (Morrill et al., 2007; Berger et al., 2011). Disparities specific to urinary
42 incontinence exist relative to race and ethnicity, education, socioeconomic status,

1 knowledge of UI and care, access to care, and treatment (Brown and Simon, 2021). These
 2 factors create barriers to health equity. Also inherent in these disparities is the concept that
 3 certain populations may be structurally vulnerable to disparate health outcomes because
 4 these groups experience individual patient and system mismatches. A few vulnerable
 5 groups identified by Brown and Simon (2021) relative to UI include Black and Native
 6 women, individuals with language deficiencies, and rural populations. Access to services
 7 (or lack thereof) for UI complicate and impact these structurally vulnerable groups further.
 8 First line treatment of urinary incontinence (stress, urgency, mixed) consists of behavioral
 9 treatments with an emphasis on improving quality of life because of their relatively non-
 10 invasive and low risk nature. Initial treatment includes lifestyle modifications and pelvic
 11 floor muscle exercise (Kegel exercises).

12
 13 Biofeedback is used as an adjunct to pelvic floor muscle exercises. By providing
 14 individuals with concurrent feedback on muscle tone, biofeedback is intended to improve
 15 the patient’s ability to perform pelvic muscle exercises. Augmented versions also use
 16 abdominal and perineal EMG recordings to demonstrate improper contraction of
 17 abdominal and gluteal muscles. Pelvic muscle exercises can aid in strengthening the
 18 voluntary periurethral and pelvic muscles needed to maintain urinary continence since
 19 contractions of these muscles raise the urethral pressure. This form of exercise is indicated
 20 for women with stress incontinence, men with incontinence following prostatic surgery,
 21 and patients with urge incontinence. Depending on the type of UI, patients are taught to
 22 contract the pelvic floor muscles, relax the detrusor and the abdominal muscles, and/or
 23 contract the sphincters. However, patients are often not compliant with their home pelvic
 24 floor muscle training programs, with research demonstrating 25%-33% adherence rates
 25 (Moen et al., 2009; Porta Roda et al., 2016; Luo et al., 2021). And for those referred for
 26 pelvic floor physical therapy, only 50%-66% attend one visit and even less complete the
 27 course of care (~3 visits) (Fullerton et al., 2022; Brown et al., 2020; Shannon et al., 2018;
 28 Shannon, Adams et al., 2018). And of those who did perform PFMT, fewer than 25%
 29 perform them adequately (Moen et al., 2009).

30
 31 Biofeedback has been suggested to be useful in teaching patients with UI pelvic muscle
 32 exercises because it relays to them whether they are contracting the right muscle(s) and
 33 provides positive reinforcements as they acquire the skill during training sessions.
 34 Biofeedback has also been suggested to improve compliance and performance of PFMT,
 35 but studies are not confirmatory in demonstrating this outcome with standard biofeedback
 36 unit use (Hagen et al., 2020; Hagen, Bugge et al., 2020). A newer at-home biofeedback
 37 device and remotely delivered program called leva® Pelvic Health System was developed
 38 to mitigate some of these issues. This device and program includes motion sensor
 39 technology with personal coaching and app technology to help patients train and strengthen
 40 their pelvic floor muscles correctly and decrease the symptoms of UI. It is physician-
 41 prescribed and does not require physical therapist involvement. Given this, the remotely

1 delivered leva® Pelvic Health System could address potential access issues for patients
2 who cannot easily receive in person treatment.

3 **Fecal Incontinence**

4 Fecal incontinence is the inability to control bowel movements and may involve leakage
5 of stool. Causes of fecal incontinence include severe constipation, chronic diarrhea,
6 overuse of laxatives, damage to the anal sphincter muscles or nerves, anal surgical
7 procedures, spinal cord injury and stroke. Treatment includes changes in dietary habits,
8 pelvic floor muscle exercises and pharmacotherapy. Fecal incontinence (FI) is common in
9 the elderly and children. Dysfunction/abnormality of one or more of many factors, such as
10 mental function, stool volume and consistency, anorectal sensation and reflexes and anal
11 sphincter function, can result in FI. There are various methods for the treatment of FI
12 including behavioral therapies, drug therapies, and surgical intervention. Various
13 biofeedback techniques have also been used in the management of FI. In particular,
14 external anal sphincter (EAS) biofeedback training has been shown to be effective in
15 treating FI. This technique teaches patients to increase the strength of contraction of their
16 EAS in response to rectal distention. There is evidence that biofeedback techniques are safe
17 and effective in the treatment of patients with fecal incontinence, especially those who have
18 some degree of rectal sensation and ability to contract the sphincter voluntarily.
19 Biofeedback training has been demonstrated to restore continence or reduce the frequency
20 of incontinence in patients with fecal incontinence with satisfactory long-term results.
21

22 **Levator Ani Syndrome**

23 Levator ani syndrome (LAS) is characterized by chronic or recurring episodes of rectal
24 pain or aching in patients with normal structural examinations of the rectum and pelvic
25 floor. Patients with these findings are considered “highly likely” to have LAS if they
26 experience tenderness on palpation of the levator muscles or to have “possible” LAS if
27 they do not experience tenderness. This pain is usually unrelated to a bowel movement,
28 and there appear to be no structural abnormalities or underlying conditions responsible for
29 the symptoms. Though the exact cause is unknown, it is commonly believed that chronic
30 tension of the pelvic floor muscles plays a role in levator ani syndrome. Another theory is
31 that inflammation in the pelvic area is a contributing factor.
32

33
34 People may be at higher risk of levator ani syndrome after childbirth or following surgery
35 on the pelvic area, anus, or spine.
36

37 **Chronic Constipation**

38 Constipation is one of the most common gastrointestinal complaints in the United States
39 affecting at least 10 % of the general population, and 25 % of the elderly. It is not a disease,
40 but a symptom of various diseases/disorders of mixed etiologies and mechanisms.
41 Constipation is defined as the occurrence of 2 or more of the following symptoms in the
42 previous 12 months (without the use of laxatives): (a) fewer than 3 bowel movements per

1 week, (b) excessive straining during at least 25 % of bowel movements, (c) a feeling of
2 incomplete evacuation after at least 25 % of bowel movements, and (d) passage of hard or
3 pellet-like stool during at least 25 % of bowel movements (Whitehead et al., 1991). Causes
4 for constipation may be colorectal (e.g., malignancy, diverticular disease, pelvic floor
5 dysfunction, and anal fissure), drug-induced (e.g., opioid analgesics, calcium and
6 aluminum-containing antacids, antidiarrheal agents, antidepressants, and antihistamines),
7 metabolic/endocrine (diabetes mellitus, hypothyroidism, hypercalcemia, and pregnancy),
8 and neurogenic (multiple sclerosis, Parkinson's disease, cerebral tumors, and
9 Hirschsprung's disease). Other possible causes include irritable bowel syndrome,
10 inadequate dietary fiber, and psychosocial problems. Pelvic floor outlet obstruction is a
11 functional disorder of evacuation involving the external anal sphincter and pelvic floor
12 voluntary musculature in which the muscles contract, rather than relax. This results in the
13 anal canal being kept tightly closed during straining at attempted defecation. Biofeedback
14 has been used successfully to teach patients with this disorder to relax the sphincter and
15 pelvic floor musculature.

16 **Migraine and Tension-type Headache**

17 It is estimated that 50 million Americans suffer from headache. It is now generally accepted
18 that about 1 in 8 adults in the developed countries has migraine headaches. Women are
19 affected 2 to 3 times more than men. This disorder predominantly affects young adults and
20 the peak incidence is between the age of 25 and 34. There are 2 major types of migraine
21 headaches: migraine with aura (classical migraine) which accounts for 15 to 18 % of all
22 migraine episodes, and migraine without aura (common migraine) which accounts for 80%
23 of all migraine attacks. Some individuals suffer from both types of migraine at different
24 times. The treatment of choice for frequent migraine sufferers is usually pharmacologic
25 prophylaxis. Avoidance strategies (loud noises, flashing lights, stress, and certain foods)
26 also constitute a very important first line approach in managing migraine. Biofeedback
27 training with or without relaxation techniques have also been shown to be effective in
28 treating migraine and tension headache. In particular, thermal biofeedback training has
29 been shown to be effective in treating migraine headache. This technique teaches patients
30 to increase the temperature of their fingers. Supposedly, dilatation of the peripheral blood
31 vessels in the hand is associated with reduced blood flow in the regions of the supra-orbital
32 and superficial temporal arteries, although the exact mechanism by which thermal
33 biofeedback improves migraine headaches is still unclear. For the management of tension
34 headache, EMG feedback has been employed primarily. Moreover, it has been shown that
35 the combination of thermal and EMG biofeedback has been effective in the control of
36 migraine, tension, and mixed migraine and tension headache. Furthermore, it has been
37 reported that relaxation techniques can produce improvements in headache. Available
38 evidence indicates that biofeedback techniques (thermal, EMG, and temporal blood
39 volume pulse biofeedback), with or without other behavioral therapies (relaxation and
40 cognitive training), are safe and effective methods for the treatment of migraine and tension
41 headache. This therapeutic modality has no side effects and does not preclude other
42

1 options. Unlike migraine and tension headache, there is a lack of published data concerning
2 the safety and effectiveness of biofeedback in the management of cluster headache.

3
4 Before participating in a biofeedback program, patients should be examined by a physician
5 to ensure that their headaches are not due to pathological conditions such as hematomas,
6 aneurysm, brain tumors, brain edema, or diseases of the eye, ear, and sinus. First line
7 approaches, including avoidance of precipitating stimuli and pharmacologic prophylaxis,
8 should have been tried and failed.

9 10 **Neuromuscular Rehabilitation**

11 Typically stroke rehabilitation includes various combinations of range of motion and
12 muscle strengthening exercises, gait and mobility training, and compensatory techniques.
13 Other therapies include neurodevelopmental based methods in which the treatment
14 incorporates neuromuscular re-education techniques where biofeedback may be employed.
15 Among biofeedback techniques employed in neuromuscular rehabilitation, EMG
16 biofeedback is the most common one. It is often utilized by stroke patients for facilitation
17 of contraction (strength) and relaxation of spasticity (inhibition). Electromyographic
18 biofeedback has also been used to treat patients with spasmodic torticollis and patients with
19 muscular atrophy resulting from surgery. The goals of EMG biofeedback in neuromuscular
20 rehabilitation include relaxation of muscles or recruitment of muscles. Relaxation of
21 muscles is performed where muscles are either trained to relax as a consequence of
22 hyperactivity that may be stress or work related or as a result of spasticity caused by central
23 nervous system dysfunction. Recruitment of muscles is to facilitate increased motor unit
24 output for movement generation or strength. This is most commonly used when muscles
25 have been weakened or inhibited as a result of injury, immobilization or surgical procedure
26 of a limb/joint.

27
28 Most biofeedback research has focused on the effects of biofeedback therapy in the
29 treatment of upper limb and lower limb motor deficits in neurological disorders (e.g.,
30 stroke). Traditionally biofeedback is presented to the patient and the clinician via visual
31 displays, acoustic or vibrotactile feedback. A recent development in rehabilitation is
32 exercising in a gaming or virtual reality (VR) environment, thus providing a novel form of
33 immersive biofeedback. With VR the measured patient activity is fed back via graphical or
34 audiovisual animations providing a realistic impression to the patient.

35 36 **EVIDENCE REVIEW**

37 **Urinary Incontinence**

38 Pelvic floor muscle training is an established treatment option for urinary incontinence.
39 Bladder training, changes in fluid intake, pharmacotherapy and surgical intervention may
40 also be indicated based on the type of incontinence. Biofeedback is an established treatment
41 modality for children and adults with stress, urge, mixed or overflow urinary incontinence
42 that is unresponsive to other nonpharmacologic modalities such as bladder training and/or

1 pelvic floor muscle training. Biofeedback may enhance awareness of body functions and
2 assist the individual in learning muscle strengthening pelvic floor exercises There are
3 several proposed methods of biofeedback which may be employed for the treatment of
4 urinary incontinence including: vaginal cones, perineometers and electromyographic
5 (EMG) systems (Holroyd-Leduc et al., 2008; Shamliyan et al., 2008; Payne, 2007). The
6 published peer-reviewed scientific literature includes systematic reviews, randomized
7 controlled trials, and case series that have reported an improvement in urinary incontinence
8 for up to two years following biofeedback (Fitz et al., 2012; Herderschee et al., 2011;
9 Desantis et al., 2011; Porena et al., 2000; Burgio et al., 2002; Herbison et al., 2002; Hunter
10 et al., 2004; Yabci et al., 2005; Dannecker et al., 2005; Burgio et al., 2006; Klijn et al.,
11 2006). In their guideline on the management of urinary incontinence in women, NICE (Sept
12 2015) stated that perineometry or pelvic floor electromyography as biofeedback should not
13 be used as a routine part of pelvic floor muscle training, but biofeedback should be
14 considered in women who cannot actively contract pelvic floor muscles in order to aid
15 motivation and adherence to therapy. In their guideline on the management of urinary
16 incontinence in women, NICE (Sept 2015) stated that perineometry or pelvic floor
17 electromyography as biofeedback should not be used as a routine part of pelvic floor
18 muscle training, but biofeedback should be considered in women who cannot actively
19 contract pelvic floor muscles in order to aid motivation and adherence to therapy. The 2017
20 American Urological Society’s (AUS) guidelines on the management of surgical treatment
21 of female stress urinary incontinence (SUI) recommends that physicians counsel patients
22 with stress urinary incontinence or stress-predominant mixed urinary incontinence who
23 wish to undergo treatment. Counseling should include available treatment options
24 including pelvic muscle floor training with or without biofeedback.

25
26 Hagen et al. (2020) assessed the effectiveness of pelvic floor muscle training (PFMT) plus
27 electromyographic biofeedback or PFMT alone for stress or mixed urinary incontinence in
28 women. Six hundred women aged 18 and older, newly presenting with stress or mixed
29 urinary incontinence between February 2014 and July 2016 were included in the study:
30 300 were randomized to PFMT plus electromyographic biofeedback and 300 to PFMT
31 alone. Participants in both groups were offered six appointments with a continence
32 therapist over 16 weeks. Participants in the biofeedback PFMT group received supervised
33 PFMT and a home PFMT program, incorporating electromyographic biofeedback during
34 clinic appointments and at home. The PFMT group received supervised PFMT and a home
35 PFMT program. PFMT programs were progressed over the appointments. The primary
36 outcome was self-reported severity of urinary incontinence (International Consultation on
37 Incontinence Questionnaire-urinary incontinence short form (ICIQ-UI SF), range 0 to 21,
38 higher scores indicating greater severity) at 24 months. Secondary outcomes were cure or
39 improvement, other pelvic floor symptoms, condition specific quality of life, women's
40 perception of improvement, pelvic floor muscle function, uptake of other urinary
41 incontinence treatment, PFMT self-efficacy, adherence, intervention costs, and quality
42 adjusted life years. Authors report that at 24 months, no evidence was found of any

1 important difference in severity of urinary incontinence between PFMT plus
2 electromyographic biofeedback and PFMT alone groups. Routine use of
3 electromyographic biofeedback with PFMT should not be recommended. Other ways of
4 maximizing the effects of PFMT should be investigated.

5
6 Wu et al. (2021) compared the efficacy of PFMT with and without EMG-BF on the cure
7 and improvement rate, PFM strength, urinary incontinence score, and quality of sexual life
8 for the treatment of stress urinary incontinence (SUI) or pelvic floor dysfunction (PFD).
9 The outcomes were the cure and improvement rate, symptom-related score, pelvic floor
10 muscle strength change, and sexual life quality. Twenty-one studies (comprising 1,967
11 patients with EMG-BF + PFMT and 1898 with PFMT) were included. Compared with
12 PFMT, EMG-BF + PFMT had benefits regarding the cure and improvement rate in SUI
13 and in PFD, and in quality of life. There was limited evidence of publication bias. PFMT
14 combined with EMG-BF achieves better outcomes than PFMT alone in SUI or PFD
15 management. Baumann et al. (2021) analyzed the specific exercise effects of supervised
16 versus unsupervised pelvic floor muscle exercise (PFME) and exercise volume on urinary
17 incontinence status after radical prostatectomy in a systematic review and meta-analysis.
18 The meta-analysis included 20 randomized controlled trials involving 2,188 men ($n = 1,105$
19 in intervention groups; $n = 1,083$ in control groups). PFME versus no PFME had a
20 beneficial effect on urinary incontinence remission at 3 months, 3-6 months, and more than
21 6 months post-surgery, with risk differences ranging from 12 to 25%. These effects were
22 particularly evident for higher volume, supervised PFME in the first 6 months post-surgery.
23 Additional biofeedback therapy appeared to be beneficial but only during the first 3 months
24 post-surgery. Authors concluded that there is good evidence that the supervised PFME
25 causes a decrease in short-term urinary incontinence rates. Unsupervised PFME has similar
26 effects as no PFME in postoperative urinary incontinence. PFME programs should be
27 implemented as an early rehabilitative measure to improve postoperative short-term
28 urinary incontinence in patients with prostate cancer.

29
30 Jacobsen et al. (2021) evaluated the efficacy of physiotherapeutic intervention with
31 biofeedback assisted PFMT in children with DV. Children referred with DV, unresponsive
32 to standard urotherapy were included in this study. All children underwent biofeedback
33 assisted PFMT sessions with a physiotherapist. Uroflowmetries and measurements of post-
34 void residual (PVR) urine were performed before and after the treatment, and the following
35 parameters were registered; daytime incontinence (DI), nocturnal enuresis (NE),
36 constipation, fecal incontinence (FI), and recurrent urinary tract infections (UTI). Other
37 concomitant treatments were noted. The primary outcomes were the resolution of DV
38 evaluated by uroflow curve configuration and PVR. Secondary outcomes were the
39 resolution of DI, NE, and the reduction of recurrent UTIs. Forty-six children (mean age 9.6
40 ± 2.4 years, 38 girls) were included in the analysis. The median period of treatment was
41 9.0 ± 8.5 months (2-9 visits). Twenty-seven (59%) children responded to treatment
42 according to one or both primary outcomes; uroflow configuration (50%) and PVR (28%).

1 DI resolved in 12 (26%) children and 27 of the 32 children, who prior to the treatment had
2 recurrent UTIs experienced no UTIs during the follow up period. The use of
3 anticholinergics was a significant negative predictor for response to treatment.
4 Biofeedback assisted PFMT can improve the symptoms in children with DV. When
5 comparing to existing literature they found a less pronounced effect of the intervention. A
6 possible explanation may be that the children enrolled in this study were recruited from a
7 tertiary referral center and were all refractory to standard urotherapy. Moreover, the
8 difference in patient characteristics and treatment protocols between different studies make
9 direct comparisons of efficacy difficult. Authors concluded that physiotherapeutic
10 intervention with biofeedback assisted PFMT seems to lead to better uroflow patterns in
11 approximately 60% of cases in DV improving the uroflow curves and PVR, however
12 improvement in uroflowmetry patterns is not necessarily reflected in the resolution of
13 incontinence or UT symptoms. The use of anticholinergics seems to be a negative predictor
14 for response to treatment.

15
16 Leonardo et al. (2022) compared biofeedback-assisted pelvic muscle floor training (PFMT)
17 and pelvic electrical stimulation (ES) as an intervention group, with PFMT or bladder
18 training (BT) as the control group, in women with an overactive bladder (OAB). Eight
19 studies involving 562 patients (comprising 204 patients with biofeedback-assisted PFMT,
20 108 patients with pelvic ES, and 250 patients who received PFMT alone or BT and lifestyle
21 recommendations only, as the control group) were included. The ES group showed
22 significant differences in terms of changes to QoL, episodes of incontinence, and the
23 number of participants cured or improved, while the biofeedback group resulted in
24 nonsignificant changes in QoL, episodes of incontinence, and the number of participants
25 cured or improved, both compared to the control group respectively. This meta-analysis
26 shows that low-frequency pelvic ES appears to be sufficient and effective as an additional
27 intervention for women with OAB in clinical practice according to improvements in the
28 subjects' QoL and reduction of symptoms. Meanwhile, biofeedback-assisted PFMT does
29 not appear to be a significant adjuvant for conservative OAB therapy.

30
31 Sam et al. (2022) compared the effectiveness of biofeedback-assisted pelvic floor muscle
32 training (PFMT) and PFMT alone on voiding parameters in women with dysfunctional
33 voiding (DV). The patients in group 1 (34 patients) were treated with biofeedback-assisted
34 PFMT, and the patients in group 2 (34 patients) were treated with PFMT alone for 12
35 weeks. The 24-hour frequency, average voided volume, maximum urine flow rate (Q_{max}),
36 average urine flow rate (Q_{ave}), post-void residual urine volume (PVR), and the validated
37 Turkish Urogenital Distress Inventory (UDI-6) symptom scores were recorded before and
38 after 12 weeks of treatment. At the end of treatment sessions, the Q_{max} and Q_{ave} values
39 of the patients in group 1 were significantly higher than those in group 2, and the PVR in
40 the patients in group 1 was significantly lower than those in group 2 (p=.026, .043, and
41 .023, respectively). The average UDI-6 symptom scores of the patients in group 1 were
42 significantly lower than those in group 2 (p=.034). Electromyography activity during

1 voiding, in group 1 was significantly lower than in group 2 (41.2 vs. 64.7, respectively,
2 $p=.009$). Authors concluded that biofeedback-assisted PFMT is more effective than PFMT
3 alone in improving clinical symptoms, uroflowmetry parameters, and EMG activity during
4 voiding.

5
6 Todhunter et al. (2022) summarized Cochrane Reviews that assessed the effects of
7 conservative interventions for treating UI in women. Authors included reviews that
8 compared a conservative intervention with 'control' (which included placebo, no treatment
9 or usual care), another conservative intervention or another active, but non-conservative,
10 intervention. Primary outcomes of interest were patient-reported cure or improvement and
11 condition-specific quality of life. Twenty-nine relevant Cochrane Reviews were included.
12 Seven focused on physical therapies; five on education, behavioral and lifestyle advice;
13 one on mechanical devices; one on acupuncture and one on yoga. Fourteen focused on non-
14 conservative interventions but had a comparison with a conservative intervention. There
15 were 112 unique trials (including 8,975 women) that had primary outcome data included
16 in at least one analysis. Stress urinary incontinence (14 reviews): Conservative intervention
17 versus control: there was moderate or high certainty evidence that pelvic floor muscle
18 training (PFMT), PFMT plus biofeedback and cones were more beneficial than control for
19 curing or improving UI. Urgency urinary incontinence (5 reviews): Conservative
20 intervention versus control: there was moderate to high-certainty evidence demonstrating
21 that PFMT plus feedback, PFMT plus biofeedback, electrical stimulation and bladder
22 training were more beneficial than control for curing or improving UI. Authors concluded
23 that there is high certainty that PFMT is more beneficial than control for all types of UI for
24 outcomes of cure or improvement and quality of life.

25
26 Yang et al. (2023) analyzed the specific exercise effects of pelvic floor muscle training
27 (PFMT) with or without biofeedback or electrical stimulation on urinary incontinence
28 rehabilitation after radical prostatectomy. A total of 18 studies with 29,925 patients were
29 included, all of which were of critically low methodological quality. Biofeedback therapy
30 seemed to show additional benefits compared to PFMT alone; however, the adjunctive role
31 of electrical stimulation remained more controversial due to the lack of strong evidence.
32 Preoperative PFMT sometimes, but not always, showed the potential to improve urinary
33 incontinence. PFMT with the guidance of a therapist could bring some benefits to the
34 patient and was more acceptable to the patient, but consumed some medical resources.
35 Authors concluded that PFMT has a good effect on improving post-radical prostatectomy
36 incontinence in men, and biofeedback can have an additional beneficial effect on patients,
37 especially in the short-term and medium-term. However, there is insufficient evidence to
38 suggest that electrical stimulation is beneficial for patients with urinary incontinence.

39
40 Johnson et al. (2023) assessed the effects of conservative interventions for managing
41 urinary incontinence after prostate surgery. Authors investigated the following key
42 comparisons: PFMT plus biofeedback versus no treatment; sham treatment or

1 verbal/written instructions; combinations of conservative treatments versus no treatment,
2 sham treatment or verbal/written instructions; and electrical or magnetic stimulation versus
3 no treatment, sham treatment or verbal/written instructions. They identified 25 studies
4 including a total of 3079 participants. Twenty-three studies assessed men who had
5 previously undergone radical prostatectomy or radical retropubic prostatectomy, while
6 only one study assessed men who had undergone transurethral resection of the prostate.
7 One study did not report on previous surgery. Most studies were at high risk of bias for at
8 least one domain. The certainty of evidence assessed using GRADE was mixed. PFMT
9 plus biofeedback versus no treatment, sham treatment or verbal/written instructions: Four
10 studies reported on this comparison. PFMT plus biofeedback may result in greater
11 subjective cure of incontinence from 6 to 12 months (1 study; n = 102; low-certainty
12 evidence). However, men undertaking PFMT and biofeedback may be less likely to be
13 objectively cured at from 6 to 12 months (2 studies; n = 269; low-certainty evidence). It is
14 uncertain whether undertaking PFMT and biofeedback has an effect on surface or skin-
15 related adverse events (1 study; n = 205; very low-certainty evidence) or muscle-related
16 adverse events (1 study; n = 205; very low-certainty evidence). Condition-specific quality
17 of life, participant adherence to the intervention and general quality of life were not
18 reported by any study for this comparison. Combinations of conservative treatments versus
19 no treatment, sham treatment or verbal/written instructions Eleven studies assessed this
20 comparison. Combinations of conservative treatments may lead to little difference in the
21 number of men being subjectively cured or improved of incontinence between 6 and 12
22 months (2 studies; n = 788; low-certainty evidence; in absolute terms: no treatment or sham
23 arm: 307 per 1000 and intervention arm: 297 per 1000). Combinations of conservative
24 treatments probably lead to little difference in condition-specific quality of life (2 studies;
25 n = 788; moderate-certainty evidence) and probably little difference in general quality of
26 life between 6 and 12 months (2 studies; n = 742; moderate-certainty evidence). There is
27 little difference between combinations of conservative treatments and control in terms of
28 objective cure or improvement of incontinence between 6 and 12 months (2 studies; n =
29 565; high-certainty evidence). However, it is uncertain whether participant adherence to
30 the intervention between 6 and 12 months is increased for those undertaking combinations
31 of conservative treatments (2 studies; n = 763; very low-certainty evidence; in absolute
32 terms: no intervention or sham arm: 172 per 1000 and intervention arm: 358 per 1000).
33 There is probably no difference between combinations and control in terms of the number
34 of men experiencing surface or skin-related adverse events (2 studies; n = 853; moderate-
35 certainty evidence), but it is uncertain whether combinations of treatments lead to more
36 men experiencing muscle-related adverse events (2 studies; n = 136; very low-certainty
37 evidence; in absolute terms: 0 per 1000 for both arms). Authors concluded that despite a
38 total of 25 trials, the value of conservative interventions for urinary incontinence following
39 prostate surgery alone, or in combination, remains uncertain. Existing trials are typically
40 small with methodological flaws. These issues are compounded by a lack of standardisation
41 of the PFMT technique and marked variations in protocol concerning combinations of
42 conservative treatments. Adverse events following conservative treatment are often poorly

1 documented and incompletely described. Hence, there is a need for large, high-quality,
2 adequately powered, randomised control trials with robust methodology to address this
3 subject.

4
5 Zhang et al. (2023) described and synthesized non-pharmacological and nonsurgical
6 interventions for male urinary incontinence from the existing literature. A total of 4602
7 studies were identified, of which 87 studies were included. Approximately 78% were
8 randomized controlled trials. More than 88% of the participants were men with prostate
9 cancer. Exercising pelvic floor muscles 30 times per day for 12 weeks was the most
10 frequently reported. Parameters of electrical stimulation were typically set up to 50 Hz and
11 300 µs for frequency and width of pulse, respectively, and lasted for 15 min. Pure pelvic
12 floor muscle training, Pilates, Yoga, whole body vibration, diaphragm/abdominal muscle
13 training, micturition interruption exercise, acupuncture, and auriculotherapy showed
14 positive effects on reducing urinary incontinence. Authors concluded that the findings
15 suggested implementing pelvic floor muscle training alone before or after surgery can both
16 prompt the recovery of continence in men after prostate cancer surgery. The decision to
17 use biofeedback or electrical stimulation to enhance the therapeutic effect of pelvic floor
18 muscle training should be approached with caution. More rigorous designed studies are
19 needed to validate the effectiveness of Traditional Chinese Medicine techniques and
20 diverse novel methods.

21
22 Höder et al. (2023) examined the scientific evidence regarding the impact of pelvic floor
23 muscle training (PFMT) with feedback from a physiotherapist and/or biofeedback on
24 urinary and anal incontinence in women during the first six months following vaginal
25 delivery, compared to treatment without feedback in a systematic review. Eight studies
26 were included, three of which showed a significant difference between groups, in favor of
27 the intervention group that received pelvic floor muscle training with feedback from a
28 physiotherapist and/or biofeedback. Due to the varying results and insufficient quality for
29 the majority of the studies, the scientific basis was considered insufficient. Authors
30 concluded that the scientific evidence for pelvic floor muscle training with feedback from
31 a physiotherapist or biofeedback on postpartum urinary and anal incontinence compared to
32 treatment without feedback is considered insufficient. Further research on the subject is
33 needed.

34
35 Remes-Troche et al. (2023) presents the formulated recommendations in 35 statements.
36 Fecal incontinence is known to be a frequent entity whose incidence increases as
37 individuals age, but one that is under-recognized. The pathophysiology of incontinence is
38 complex and multifactorial, and in most cases, there is more than one associated risk factor.
39 Even though there is no diagnostic gold standard, the combination of tests that evaluate
40 structure (endoanal ultrasound) and function (anorectal manometry) should be
41 recommended in all cases. Treatment should also be multidisciplinary and general
42 measures and drugs (lidamidine, loperamide) are recommended, as well as non-

1 pharmacologic interventions, such as biofeedback therapy, in selected cases. Likewise,
2 surgical treatment should be offered to selected patients and performed by experts.

4 **Fecal Incontinence**

5 Biofeedback has been proposed for the treatment of fecal incontinence, and overall, results
6 from systematic reviews and randomized controlled trials reported that biofeedback may
7 help improve this condition in certain patients. However, studies primarily include small
8 heterogeneous patient populations and diagnosis, short-term follow-up, and various
9 biofeedback regimens and methods. Patient selection criteria with appropriate types of
10 biofeedback regimens have not been established. In the guideline on the management of
11 fecal incontinence, NICE (2007) stated that adults who have persistent fecal incontinence
12 after initial management should be considered for special continence services including
13 biofeedback. Due to the limited evidence, biofeedback is not recommended as a first line
14 therapy. Brazzelli et al. (2011) conducted a systematic review of randomized and quasi-
15 randomized controlled trials to assess the effectiveness of behavior and/or cognitive
16 interventions, including biofeedback, for the treatment of children with fecal incontinence.
17 Twenty-one trials ($n=1371$) met inclusion criteria. Follow-ups ranged from 4–24 months
18 with two trials reporting no follow-up following cessation of treatment. Combined results
19 of nine trials showed higher rates of persistent symptoms of fecal incontinence for up to 12
20 months when biofeedback was added to conventional treatment (e.g., laxatives, toilet
21 training, dietary advice, behavior modification). Based on this data, the authors concluded
22 that there was “no evidence” that biofeedback training added any benefit to conventional
23 therapy for the management of functional fecal incontinence nor was there enough data to
24 assess the effectiveness of biofeedback for the management of organic fecal incontinence
25 in children. Norton and Cody (2012) conducted a systematic review of randomized and
26 quasi-randomized controlled trial to evaluate biofeedback and/or anal sphincter exercises
27 for the treatment of fecal incontinence in adults. Twenty-one studies ($n=1525$) met
28 inclusion criteria. Two biofeedback studies reported follow-ups at nine months and five
29 studies reported follow-ups at one year, but most studies reported no follow-up following
30 cessation of treatment. The authors stated that they found no evidence that biofeedback
31 provided any benefit over any other treatment (e.g., dietary modification, bulking agents,
32 pelvic floor exercises) for fecal incontinence. Evidence on patient selection criteria is
33 lacking. Overall, the limited number of studies with methodological weaknesses, including
34 incomplete outcome data, did not allow for definitive assessment of the role of biofeedback
35 in the treatment of adults with fecal incontinence.

36
37 Vonthein et al. (2013) conducted a systematic review of randomized controlled trials to
38 evaluate the effectiveness of biofeedback (BF) and electrical stimulation (ES) for the
39 treatment of fecal incontinence. Included studies evaluated BF, ES, BF plus ES, and/or
40 pelvic floor exercises as a second-line therapy in adults who had no obvious need for
41 surgery. The included studies also had to report patient-related outcomes (i.e., remission,
42 response, and/or disease-related quality of life). Thirteen trials met inclusion criteria. In 12

1 trials, at least one study group received biofeedback typically in combination with ES or
2 another modality. One study compared BF alone vs. ES alone and reported no significant
3 differences in FI in either group following treatment. Two studies reported a significant
4 improvement in the FI severity index, number of days with FI, anal squeeze and/or quality
5 of life. However, most studies reported no significant difference with the addition of
6 biofeedback. The authors noted that BF seemed to be better than no BF and concluded that
7 ES plus BF seemed to be the most effective treatment. Limitations of the studies
8 investigating biofeedback for fecal incontinence included: small patient populations;
9 heterogeneous populations (e.g., obstetrical trauma, elderly women); short-term follow-
10 ups, conflicting outcomes, and missing data. The Italian Society of Colorectal Surgery
11 (SICCR) and the Italian Association of Hospital Gastroenterologists (AIGO) joint
12 committee developed a 2015 consensus statement for the treatment of fecal incontinence
13 (FI). In the discussion of rehabilitative treatment for functional FI, the Committee reported
14 that randomized controlled studies sustain the use of biofeedback. According to SICCR, a
15 few studies suggested that adding biofeedback does not enhance the outcome of
16 conservative management while other studies suggested that biofeedback and pelvic floor
17 exercises be considered as a first-line option for patients who fail treatment with dietary
18 changes, devices, or drugs. Since there are no side effects, failure of biofeedback would
19 not affect decisions regarding future therapy. Biofeedback with kinesitherapy (movement
20 therapy) may also be a useful treatment. One study suggested biofeedback can be helpful
21 after sphincteroplasty. The authors noted that techniques used for biofeedback and other
22 modalities vary greatly and results of studies are not comparable (SICCR, 2015).
23 Limitations of the studies evaluating biofeedback for the treatment of FI included: small,
24 heterogeneous patient populations; heterogeneity of diagnosis, biofeedback methods and
25 outcome measures; inconsistent statistically improved outcomes (e.g., embarrassment
26 score, severity of FI, number of FI occurrences) across studies; lack of a control group; and
27 conflicting outcomes. In some studies outcomes were not generalizable due to the diagnosis
28 (e.g., obstetrical trauma).

29
30 The American Society of Colon and Rectal Surgeons (ASCRS) (2015) stated that
31 biofeedback should be considered as an initial treatment of fecal incontinence in motivated
32 patients with some preserved voluntary sphincter contraction. ASCRS noted that the
33 benefits are variable and standard care (e.g., advice and education) alone have been shown
34 to be as effective as biofeedback therapy. The recommendation is based on moderate-
35 quality evidence and ASCRS noted that larger, well-designed studies are needed to make
36 any definitive conclusions. In their 2015 guidelines for the efficacy of biofeedback for
37 anorectal disorders, the American Neurogastroenterology and Motility Society (ANMS)
38 and the European Society of Neurogastroenterology and Motility (ESNM) recommended
39 biofeedback for the short- and long-term treatment of fecal incontinence for patients who
40 have not responded to conservative medical treatment (e.g., antidiarrheals, fiber
41 supplements). The guideline noted that treatment success is best defined as a 50% reduction
42 in episodes of fecal incontinence, which has not been used in clinical trials. Other

1 publications support this (Patcharatrakul and Rao, 2018; Rao et al., 2016). The Societies
2 recommendation was based on nonrandomized studies rated as fair evidence and they noted
3 that further research is needed to standardize the treatment protocols and the training of
4 biofeedback therapists (Rao et al., 2015). Overall, studies investigating the effectiveness
5 of biofeedback for fecal incontinence included small, heterogeneous patient populations
6 and treatment regimens with short-term follow-ups. Biofeedback was used as an adjunctive
7 therapy with various modalities. Outcomes were conflicting and several studies reported
8 that no significant differences were seen with biofeedback. Because some studies included
9 defined subpopulations (e.g., females with impaired fecal incontinence after obstetric anal
10 sphincter injury) outcomes were not generalizable.

11
12 The Agency for Healthcare Research and Quality (AHRQ) conducted a 2016 comparative
13 effectiveness review on treatments for fecal incontinence (FI) in adults. Thirteen
14 randomized controlled trials examined pelvic floor muscle training (PFMT) and PFMT
15 with biofeedback (PFMT-BF). Enrolled adults were mostly female with mixed FI
16 etiologies. Meta-analysis was not possible due to the numerous outcomes that were used.
17 PFMT-BF was the most frequently studied intervention. Outcomes included the frequency
18 and severity of FI, quality of life and perceived improvement. AHRQ found that the
19 evidence was insufficient to support PFMT-BF vs. standard care (e.g., dietary fiber, stool-
20 modifying drugs, and/or advice). Low-strength evidence showed that PFMT-BF with
21 electrostimulation was no more effective than PFMT-BF alone on FI severity and FI quality
22 of life over two to three months. Although PFMT-BF showed improvement in FI outcomes,
23 the improvements were not significantly different from the comparison groups. AHRQ
24 noted that future studies should focus on longer term effects and attempt to identify
25 subgroups of adults by FI etiology that might benefit from specific interventions.

26
27 Li et al. (2022) systematically reviewed and synthesized the evidence on the effectiveness
28 of biofeedback therapy in patients with bowel dysfunction following rectal cancer surgery.
29 Randomized controlled trials (RCTs), cohort studies, and case series studies were included
30 for adults with bowel dysfunction following rectal cancer surgery. All participants received
31 an intervention of biofeedback treatment. Any outcomes that can evaluate the patient's
32 bowel function were the primary research endpoint, while the quality of life was the second
33 endpoint. Key findings included significant improvements in bowel function as well as
34 health-related quality of life after biofeedback therapy. Authors concluded that although
35 biofeedback therapy may improve intestinal function and quality of life as well as anal
36 function after surgery, patient satisfaction is still unclear. Due to the scarcity of data, good-
37 quality research is required to delve deeper.

38
39 Pun et al. (2024) investigated the effectiveness of physiotherapy interventions compared
40 to control conditions on fecal incontinence (FI) and quality of life (QoL) following
41 colorectal surgery. Ten trials were included. Meta-analysis revealed statistically significant
42 improvements in lifestyle, coping behavior, and embarrassment components of QoL

1 among individuals receiving pelvic floor muscle training (PFMT) compared with those
2 receiving usual care (UC). Meta-analysis showed biofeedback to be significantly more
3 effective than UC in enhancing anal resting pressure (ARP), maximum squeeze pressure
4 (MSP), and rectal resting pressure (RRP). Meta-analysis also found PFMT combined with
5 biofeedback to be significantly more effective than PFMT alone for ARP, MSP, and RRP.
6 Authors concluded that PFMT combined with biofeedback was more effective than PFMT
7 alone, but both interventions delivered alone were superior to UC. Future studies remain
8 necessary to optimize and standardize the PFMT parameters for improving QoL among
9 individuals who experience FI following CRC surgery.

10 **Levator Ani Syndrome**

11 In their 2015 guidelines for the efficacy of biofeedback for anorectal disorders, the
12 American Neurogastroenterology and Motility Society (ANMS) and the European Society
13 of Neurogastroenterology and Motility (ESNM) recommended biofeedback may be useful
14 in the short-term treatment of Levator Ani Syndrome with dyssynergic defecation (Level
15 II, Grade B) (Rao et al., 2015). Reports of biofeedback treatment for chronic functional
16 anorectal pain have shown inconsistent results, and most of these were small and
17 uncontrolled (46). However, a RCT of 157 well-characterized patients with LAS compared
18 three treatments: biofeedback to teach pelvic floor muscle relaxation, electrogalvanic
19 stimulation (EGS) to relax the pelvic floor, and digital massage of the levator muscles
20 (Chiarioni et al., 2010). The primary outcome measure was the subjects' report of adequate
21 pain relief. Key to the interpretation of the study was an a priori decision to test for
22 tenderness when traction was applied to the levator ani muscles during digital rectal
23 examination, and patients were stratified into the three treatment arms based on the
24 presence or absence of tenderness. Among patients with tenderness on physical
25 examination, adequate relief was reported by 87% with biofeedback, 45% with EGS and
26 22% with digital massage. However, none of these three treatments were effective in
27 patients who did not report tenderness on physical examination (Chiarioni et al., 2010).
28 The mixed results reported in previous biofeedback studies most likely were a consequence
29 of failure to stratify patients based on the presence or absence of levator ani tenderness.
30 Other publications also support this (Patcharatrakul and Rao, 2018; Rao et al., 2016).
31 Biofeedback therapy has also been used to treat Solitary Rectal Ulcer Syndrome (SRUS)
32 in open, short-term, small sized (less than 20 patients) studies. Inclusion criteria,
33 physiological investigations and outcome parameters were variable. Biofeedback therapy
34 was associated with symptom improvement in at least two thirds of patients with some
35 histological improvement. Most notably, the highest successful outcome was reported
36 when SRUS was associated with dyssynergic defecation (DD) (Rao et al., 2015).
37 Narayanan et al. (2019) authored a review to update practitioners on recent advances and
38 to identify practical obstacles to providing biofeedback therapy. Authors summarized
39 recent findings: the efficacy and safety of biofeedback therapy evaluated in defecatory
40 disorders, fecal incontinence, and levator ani syndrome. They note that based on literature,
41 biofeedback therapy is effective for managing defecatory disorders, fecal incontinence, and
42

1 levator ani syndrome. Biofeedback therapy is recommended for patients with fecal
2 incontinence who do not respond to conservative management. A subset of patients with
3 levator ani syndrome who have dyssynergic defecation are more likely to respond to
4 biofeedback therapy.

6 **Chronic Constipation**

7 The evidence in the published peer-reviewed scientific literature supports the use of
8 biofeedback for the treatment of constipation in adults. Significant improvements in
9 constipation with biofeedback have been reported in systematic reviews, meta-analysis and
10 randomized controlled trials (Skardoon et al., 2017; Woodward et al., 2014; Enck et al.,
11 2009; Koh et al., 2008; Heyman et al., 2007; Rao et al., 2007; Chiarioni et al., 2006;
12 Heyman et al., 2003). Biofeedback for the treatment of constipation in children is not well
13 established and has not been proven to add additional benefit to established conventional
14 therapy (Brazzelli et al. 2006; Brazzelli et al. 2004). The 2010 guideline (updated 2017) on
15 the management of constipation in children and young adults by the National Institute for
16 Health and Clinical Excellence (NICE) (United Kingdom) stated that biofeedback should
17 not be used for ongoing treatment in children and young people with idiopathic
18 constipation. Meta-analysis showed no improvement in outcomes when conventional
19 treatment (e.g., use of laxatives, advice on a high-fiber diet, attempting defecation after
20 meals) was compared to conventional treatment plus biofeedback. In a 2014 evidence-
21 based guideline on the evaluation and treatment of functional constipation in infants and
22 children, the North American Society for Pediatric Gastroenterology, Hepatology, and
23 Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology,
24 Hepatology, and Nutrition (ESPGHAN) concluded that the evidence did not support the
25 use of behavioral therapy or biofeedback in the treatment of childhood constipation
26 (Tabbers et al., 2014).

27
28 The 2013 American Gastroenterological Association’s (AGA) position statement on
29 constipation for adults stated that biofeedback improves symptoms in more than 70% of
30 patients with defecatory disorders. Biofeedback can be used to train patients to relax their
31 pelvic floor muscles during straining and to correlate relaxation and pushing to achieve
32 defecation. The success of the therapy depends on the motivation of the patient and
33 therapist, frequency and intensity of the retraining, and involvement of behavioral
34 psychologist and dieticians. AGA “strongly recommends” “based on high quality
35 evidence” that biofeedback be used rather than laxatives for defecatory disorders which are
36 primarily characterized by impaired rectal evacuation from inadequate rectal propulsive
37 forces and/or increased resistance to evacuation. In practice guidelines on the management
38 of constipation, the American Society of Colon and Rectal Surgeons (ASCRS) (2016)
39 states that in general, biofeedback should be used to treat slow-transit constipation and
40 pelvic floor dyssynergia before subtotal colectomy. ASCRS recommended biofeedback as
41 a first-line treatment option for patients with constipation due to symptomatic pelvic floor
42 dyssynergia.

1 The American Neurogastroenterology and Motility Society (ANMS) and the European
 2 Society of Neurogastroenterology and Motility (ESNM) (Rao et al., 2015) provided
 3 evidence-based recommendations on the efficacy of biofeedback for anorectal disorders.
 4 The Societies conducted a review of the literature and used the U.S. Preventive Services
 5 Task Force evidence criteria to grade the recommendations. The Societies’
 6 recommendations included the following:

- 7 • Biofeedback is recommended for the short-term and long-term treatment of
 8 constipation with dyssynergic defecation (Level I, Grade A: evidence from at least
 9 one properly randomized controlled trial; good evidence; strongly recommends that
 10 clinicians routinely provide).
- 11 • Biofeedback may be useful for the short-term treatment of Levator Ani Syndrome
 12 with dyssynergic defecation (Level II, Grade B: nonrandomized studies; fair
 13 evidence; recommends that clinicians routinely provide) and solitary rectal ulcer
 14 syndrome with dyssynergic defecation (Level III, Grade C; opinions of authorities,
 15 based on clinical experience, descriptive studies and case reports or reports of
 16 expert committees; fair evidence; makes no recommendation).
- 17 • Biofeedback therapy is not recommended for the routine treatment of children with
 18 functional constipation, with or without overflow fecal incontinence. (Level I,
 19 Grade D; evidence from at least one properly randomized controlled trial;
 20 recommends against its use).

21
 22 The French National Society of Coloproctology (Vitton et al., 2018) offers clinical practice
 23 recommendations for chronic constipation on the basis of the data in the current literature,
 24 including those on recently developed treatments. Most are noninvasive, and the main
 25 concepts include the following: stimulant laxatives are now considered safe drugs and can
 26 be more easily prescribed as a second-line treatment; biofeedback therapy remains the gold
 27 standard for the treatment of anorectal dyssynergia that is resistant to medical treatment.
 28 Moore and Young (2020) assessed the effectiveness of biofeedback therapy for
 29 dyssynergic defecation using global clinical improvement as the primary outcome, and
 30 resolution of the dyssynergic pattern on anorectal physiology and quality of life as
 31 secondary outcomes in a systematic review and meta-analysis. Eleven trials including 725
 32 participants were included in the narrative review. Sixty-three percent of patients treated
 33 with biofeedback reported clinical improvement. Six studies included in the meta-analysis
 34 showed biofeedback superior to non-biofeedback therapy for the primary outcome.
 35 Heterogeneity between trials and overall risk of bias was high. Authors concluded that
 36 biofeedback therapy is recommended for patients referred to tertiary units with dyssynergic
 37 defecation who fail conservative therapy. In a paper on biofeedback for defecatory
 38 disorders, Hite and Curran (2021) state that biofeedback has demonstrated efficacy in the
 39 treatment of chronic constipation with dyssynergic defecation, fecal incontinence, and low
 40 anterior resection syndrome. Evidence for the use of biofeedback in levator ani syndrome
 41 is conflicting. In comparing biofeedback to pelvic floor muscle training alone, studies
 42 suggest that biofeedback is superior therapy.

1 Wegh et al. (2021) evaluated the effectiveness and safety of non-pharmacological
 2 interventions for the treatment of childhood functional constipation functional
 3 constipation. 52 RCTs were included with 4668 children, aged between 2 weeks and 18
 4 years, of whom 47% were females. Studied interventions comprised of gut microbiome-
 5 directed interventions, other dietary interventions, oral supplements, pelvic floor-directed
 6 interventions, electrical stimulation, dry cupping, and massage therapy. An overall high
 7 risk of bias was found across the majority of studies. Meta-analyses for treatment success
 8 and/or defecation frequency, including 20 RCTs, showed abdominal electrical stimulation
 9 ($n=3$), Cassia Fistula emulsion ($n=2$), and a cow's milk exclusion diet ($n=2$ in a
 10 subpopulation with constipation as a possible manifestation of cow's milk allergy) may be
 11 effective. Evidence from RCTs not included in the meta-analyses, indicated that some
 12 prebiotic and fiber mixtures, Chinese herbal medicine (Xiao'er Biantong granules), and
 13 abdominal massage are promising therapies. In contrast, studies showed no benefit for the
 14 use of probiotics, synbiotics, an increase in water intake, dry cupping, or additional
 15 biofeedback or behavioral therapy. We found no RCTs on physical movement or
 16 acupuncture. Authors concluded that more well-designed high quality RCTs concerning
 17 non-pharmacological treatments for children with functional constipation are needed
 18 before changes in current guidelines are indicated.

19
 20 Sadeghi et al. (2023) completed a comprehensive review on diagnosis and management of
 21 dyssynergic defecation (DD). Relative to biofeedback training (BFT), studies have clearly
 22 shown that BFT is more effective than dietary modification, laxatives, diazepam, muscle
 23 relaxants, placebo, and sham biofeedback, has longer persistency and no adverse effect.
 24 They concluded that biofeedback therapy could improve bowel movements, stool
 25 consistency, straining, sensation of incomplete evacuation, quality of life, and para-clinical
 26 features of DD in diagnostic testing.

27 28 **Migraine and Tension-type Headache**

29 Biofeedback is a standard treatment option for migraine and tension headaches. Systematic
 30 reviews and randomized controlled trials have reported that biofeedback is effective in
 31 reducing the severity and frequency of these headaches in adults and children (Vasudeva
 32 et al., 2003; Eccleston et al., 2004; Kaushik et al., 2005; Nestoriuc and Martin, 2007). After
 33 conducting a meta-analysis of 55 randomized controlled trials, including 1718 patients
 34 assigned to biofeedback and 511 patients assigned to controls, Nestoriuc and Martin (2007)
 35 stated that biofeedback could be recommended as an evidence-based behavioral treatment
 36 option for the prevention of migraine.

37
 38 Martina et al. (2023) presented an up-to-date evaluation of the efficacy of EMG-
 39 biofeedback (EMG-BFB) for primary headaches and to address possible mediators of
 40 outcome. A total of 3059 articles were identified through the database searches. 29 articles,
 41 involving 1342 participants, met the inclusion criteria for the systematic review; of them,
 42 4 were included in the meta-analysis. Ten studies reported a significant improvement in

1 the EMG-BFB group with respect to the control group. Meta-analyses show a reduction in
 2 the intensity of attacks in patients subjected to EMG-BFB based on 293 patients). Authors
 3 concluded that EMG-BFB represents a non-pharmacological approach to headache
 4 treatment as shown via qualitative synthesis, despite not impressive results, this technique
 5 can be particularly useful in pediatric or in adult patients who cannot undergo drug
 6 therapies. Quantitative synthesis revealed a promising effect in the intensity of headaches
 7 attacks. Moreover, no significant effect was found about the effectiveness of EMG-BFB in
 8 the reduction of frequency and durations of headache attacks.

9 **Neuromuscular Rehabilitation**

10 There is sufficient evidence that EMG biofeedback is safe and effective for neuromuscular
 11 rehabilitation in patients who suffered from strokes (Giggins et al., 2013; Stanton et al.,
 12 2017). However, there is insufficient evidence that EMG biofeedback is effective as a
 13 rehabilitation modality for patients with spinal cord injury and in patients with spasmodic
 14 torticollis (Giggins et al., 2013). Additionally, although there is limited evidence that EMG
 15 biofeedback is effective in enhancing the return to full active knee extension and peak
 16 torque of the quadriceps femoris muscle following knee surgeries, there is little data on
 17 how these improvements translate clinically into improved functional outcomes (Giggins
 18 et al., 2013). For patients to potentially benefit from EMG biofeedback, they need to have
 19 some volitional muscle activity but remain disabled with no receptive aphasia. And
 20 biofeedback should be used when other standard forms of therapy have failed.

21
 22
 23 Pollock et al. (2003) conducted a systematic review on the recovery of postural control and
 24 lower limb function following stroke. The objective was to determine if outcomes were
 25 different if the physiotherapy treatment was based on orthopedic, neurophysiology, motor
 26 learning principles or a mixture of these modalities. The review included randomized or
 27 quasi-randomized controlled trials with interventions of physiotherapies, including
 28 biofeedback. Outcomes measured the degree of disability and motor impairment. Eighteen
 29 studies were categorized as EMG biofeedback and fifteen studies as positional
 30 biofeedback. The authors concluded that there was insufficient evidence to determine if
 31 one method was more effective than the other. Woodford and Price (2007) conducted a
 32 meta-analysis of 13 studies ($n=269$) on the use of electromyographic biofeedback (EMG-
 33 BFB) for the recovery of motor function following a stroke. The analysis included
 34 randomized controlled trials and quasi-randomized controlled trials that compared
 35 physiotherapy or exercises or physical therapy alone to these treatment modalities plus
 36 EMG/EMG-BFB. There were variations in the time from stroke to randomization (35 to
 37 1,140 days), and the length of the studies ranged from four to 16 weeks. Small sample sizes
 38 ($n=10-40$) were also a limitation of the studies. Outcome criteria included changes in motor
 39 strength, range of motion, stride length, gait speed, functional ability, and gait quality score.
 40 Overall, the data did not demonstrate a positive effect on the outcomes. The authors
 41 concluded that EMG-BFB did “not appear to have a positive benefit for recovery after
 42 stroke,” and it could not be recommended as a routine treatment modality. Tate and Milner

1 (2010) conducted a systematic review of randomized controlled trials ($n=7$) to evaluate the
2 effectiveness of biofeedback in treating gait abnormalities. The types of biofeedback
3 included real-time kinematic, temporospatial and kinetic. In five studies the patient
4 population ($n=105$) was status-post stroke. One study included 42 patients with hip or knee
5 replacement, hip fracture or amputation and one study included 28 patients' status-post
6 total hip replacement. There was a large range in the structure of the treatment protocol
7 (e.g., treatment time, frequency, duration) and meta-analysis was not performed because
8 of the wide variety of study designs, methodologies, and outcome measures. Although
9 some studies reported short-term improvement, long-term outcomes were not reported and
10 whether improvements were maintained is unknown. The authors concluded that there was
11 insufficient data to make a guideline recommendation for biofeedback for gait training.

12
13 Zijlstra et al. (2010) conducted a systematic review of randomized controlled trials ($n=17$)
14 and comparative studies ($n=4$) to evaluate the effectiveness of biofeedback training for
15 balance and/or mobility in older adults. Twelve studies included post-stroke patients, six
16 included frail older adults in a care center and three studies included lower limb amputation
17 and/or hip surgery. The biofeedback was visual and/or audio. The studies were determined
18 to be of moderate quality with variations in analyses and outcomes. Due to the inability to
19 perform quantitative analysis and the absence of large-scale randomized controlled trials,
20 definitive conclusions could not be made. The addition of biofeedback during gait training
21 did not seem to improve disability and mobility functioning. In their 2010 guidelines on
22 stroke rehabilitation, the Department of Veterans Affairs, Department of Defense,
23 American Heart Association and American Stroke Association recommended EMG
24 biofeedback as a treatment modality for pain control when appropriate. However, “due to
25 methodological flaws in current studies, further research is indicated to assess the efficacy
26 of biofeedback as an adjunct to conventional therapy for post-stroke patients.” Doğan-
27 Aslan et al. (2012) evaluated the effect of electromyographic biofeedback (EMG-BF)
28 treatment on wrist flexor muscle spasticity, upper extremity motor function, and ability to
29 perform activities of daily living in patients with hemiplegia following stroke. A total of
30 40 patients were enrolled and were randomly assigned to two groups: a group treated with
31 EMG-BF (study group) and an untreated (control) group. Both groups participated in a
32 hemiplegia rehabilitation program consisting of neurodevelopmental and conventional
33 methods. In addition, the study group received 3 weeks of EMG-BF treatment, 5 times a
34 week, for 20 minutes per session at hemiplegic side wrist flexors. Clinical findings were
35 assessed before and after rehabilitation using the Ashworth scale (AS), Brunnstrom's stage
36 (BS) of recovery for hemiplegic arm and hand, the upper extremity function test (UEFT),
37 the wrist and hand portion of the Fugl-Meyer scale (FMS), goniometric measurements of
38 wrist extension, surface EMG potentials, and the Barthel Index (BI). There was no
39 statistically significant difference between the two groups in terms of baseline measures.
40 There also was no statistically significant difference in the pretreatment values between
41 two groups. Authors noted statistically significant improvements posttreatment in the AS,
42 BS, UEFT, goniometric measurements of wrist extension, and surface EMG potentials in

1 the study group. They also noted statistically significant differences in the wrist and hand
2 portion of the FMS and the BI in both groups, but with significantly greater improvements
3 in the study group. Authors concluded that findings indicate a positive effect of EMG-BF
4 treatment in conjunction with neurodevelopmental and conventional methods in
5 hemiplegia rehabilitation.

6
7 Stanton et al. (2011) conducted a systematic review and meta-analysis of 22 randomized
8 and quasi-randomized controlled trials to evaluate the effectiveness of biofeedback in
9 enhancing lower-limb training for sitting, standing up, standing, or walking following a
10 stroke. Included clinical trials used various forms of biofeedback including any signal
11 (position, EMG) via any sense (visual, auditor, tactile) during the practice of the whole
12 activity. Based on pooled data from 17 trials ($n=411$) biofeedback improved lower limb
13 activities compared to usual therapy or placebo in the short-term (i.e., 1 to 5 months
14 following cessation of therapy). However, the authors noted that there was substantial
15 heterogeneity of the low-quality trials using any form of biofeedback; lack of blinding of
16 subjects and therapists; possible small trial bias and selection bias based on intervention in
17 the studies used for meta-analysis; and only half of the trials measured outcomes for any
18 length of time following cessation of therapy. Well-designed randomized controlled trials
19 with long-term results are needed to support the effectiveness of biofeedback in stroke
20 patients. Stanton et al. (2017) completed on systematic review with meta-analysis to
21 determine if biofeedback during the practice of lower limb activities after stroke is more
22 effective than usual therapy in improving those activities. Outcome measures were activity
23 measures congruent with the activity trained. Eighteen trials including 429 participants met
24 the inclusion criteria. The quality of the included trials was moderately high, with a mean
25 PEDro score of 6.2 out of 10. Results demonstrated that biofeedback improved
26 performance of activities more than usual therapy. Authors concluded that biofeedback is
27 more effective than usual therapy in improving performance of activities. They also stated
28 that further research is required to determine the long-term effect on learning and given
29 that many biofeedback machines are relatively inexpensive, biofeedback could be utilized
30 widely in clinical practice. Wattoo et al. (2018) investigated the therapeutic
31 interventions reported in the research literature and synthesize their effectiveness in
32 improving upper limb (UL) function in the first 4 weeks poststroke. A total of 104 trials
33 (83 RCTs, 21 nonrandomized studies) were included ($N=5,225$ participants). Evidence was
34 found to support supplementary use of biofeedback and electrical stimulation. Authors
35 concluded that use of modified constraint-induced movement therapy (mCIMT) and task-
36 specific training was supported, as was supplementary use of biofeedback and electrical
37 simulation, within the acute phase poststroke.

38
39 Lirio-Romero et al. (2021) examined the effects of a 6-week surface electromyographic
40 biofeedback intervention on the re-learning of upper extremity motor function in subjects
41 with paretic upper extremity after stroke. Thirty-eight participants in the sub-acute post-
42 stroke stage were recruited and randomly allocated into either the surface

1 electromyographic biofeedback (sEMG-BFB) or sham biofeedback (BFB) groups. The
2 sEMG-BFB group ($n=19$) received the intervention focused on re-learning scapulothoracic
3 control during arm-reaching tasks involving shoulder abduction. The sham BFB group
4 ($n=19$) received a sham intervention. In the short term, a 6-week sEMG-BFB intervention
5 effectively improved paretic upper limb motor function. Future research is needed to
6 determine if the sEMG-BFB intervention has any long-term effects. Spencer et al. (2021)
7 evaluated the state of the current evidence regarding the effectiveness of biofeedback for
8 post-stroke gait training. Their overall goal was to determine whether gait biofeedback was
9 effective at improving stroke gait deficits while also probing why and for whom gait
10 biofeedback may be an efficacious treatment modality. Their literature review showed that
11 the effects of gait biofeedback on post-stroke walking dysfunction are promising but are
12 inconsistent in methodology and therefore results. There is a need for larger-sample studies
13 that directly compare different feedback parameters, employ more uniform experimental
14 designs, and evaluate characteristics of potential responders. However, as these
15 uncertainties in existing literature are resolved, the application of gait biofeedback has
16 potential to extend neurorehabilitation clinicians' cues to individuals with post-stroke gait
17 deficits during ambulation in clinical, home, and community settings, thereby increasing
18 the quantity and quality of skilled repetitions during task-oriented stepping training.

19
20 Balbinot et al. (2022) summarized the most common sEMG techniques used to address
21 clinically relevant neurorehabilitation questions. Authors focused on the role of sEMG
22 assessments in the clinical practice and research studies on neurorehabilitation after spinal
23 cord injury (SCI), and how sEMG reflects the changes observed with rehabilitation. Of
24 4,522 references captured in the primary database searches, 100 references were selected
25 and included in the scoping review. The focus of the studies was on neurorehabilitation
26 using sEMG biofeedback, brain stimulation, locomotor training, neuromuscular electrical
27 stimulation (NMES), paired-pulse stimulation, pharmacology, posture and balance
28 training, spinal cord stimulation, upper limb training, vibration, and photobiomodulation.
29 Authors concluded that most studies employed sEMG amplitude to understand the effects
30 of neurorehabilitation on muscle activation during volitional efforts or reduction of
31 spontaneous muscle activity (e.g., spasms, spasticity, and hypertonia). Further studies are
32 needed to understand the long-term reliability of sEMG amplitude, to circumvent
33 normalization issues, and to provide a deeper physiological background to the different
34 sEMG analyses. This scoping review reveals the potential of sEMG in exploring promising
35 neurorehabilitation strategies following SCI and discusses the barriers limiting its
36 widespread use in the clinic.

37
38 Li et al. (2023) evaluated the effect of different traditional Chinese and western medicine
39 rehabilitation techniques on motor dysfunction after stroke using a network meta-analysis.
40 Seventy-four randomized controlled trials involving nine rehabilitation techniques and
41 5128 patients were included. The results of network meta-analysis showed the following
42 orders regarding improvement of the total scores of Fugl-Meyer Assessment, Action

1 Research Arm Test, and Berg Balance Scale: biofeedback therapy > mirror therapy >
2 repetitive transcranial magnetic stimulation > acupuncture therapy > transcranial direct
3 current stimulation > Taichi > common therapy, virtual reality > transcranial direct current
4 stimulation > repetitive transcranial magnetic stimulation > mirror therapy > common
5 therapy, and acupuncture therapy > virtual reality > neuromuscular electrical stimulation
6 > mirror therapy > common therapy > transcranial direct current stimulation, respectively.
7 Authors concluded that biofeedback therapy had the best comprehensive effect, while
8 virtual reality was the best intervention for improving the index of action research arm test
9 and Fugl-Meyer Assessment-lower extremity. Acupuncture therapy improved lower limb
10 balance function.

11
12 Tiryaki et al. (2023) investigated the effectiveness of a rehabilitation program with
13 electromyographic biofeedback compared with the control group on patients with massive
14 rotator cuff tear. Forty-six adults with massive rotator cuff tears, randomly assigned to 2
15 groups (23 electromyographic biofeedback group vs. 23 control group). The
16 electromyographic biofeedback group (experimental group) performed the exercises under
17 the guidance of electromyographic biofeedback, unlike the control group. All patients
18 underwent a 45-minute training session a day, 3 times a week over a 6-wk duration, and
19 followed up until 1-year. The outcome measures were American Shoulder and Elbow
20 score, shoulder flexion strength, shoulder range of motion, Numeric Pain Rating Scale, and
21 Global Rating of Change Scale. Compared with the control group, the electromyographic
22 biofeedback group demonstrated a significant change in shoulder flexion strength and
23 patient satisfaction from baseline to 6 wks (posttraining) and from baseline to 12-mo
24 follow-up. There were significant improvements in within groups statistics for American
25 Shoulder and Elbow score, shoulder flexion strength, shoulder range of motion, and
26 Numeric Pain Rating Scale in both groups. Authors conclude that the results demonstrate
27 that deltoid-focused structured rehabilitation program combined with electromyographic
28 biofeedback can be used to increase shoulder flexion strength and patient satisfaction in
29 conservative treatment of massive rotator cuff tear.

30
31 Wang et al. (2023) evaluated whether electromyographic biofeedback can improve upper
32 and lower limb dysfunction in stroke patients. The analyses included 10 studies enrolling
33 a total of 303 participants. Electromyographic biofeedback therapy can effectively improve
34 limb function after stroke and in subgroup analyses, the effect sizes of short-term effect
35 was significant, but the long-term was not. In addition, electromyographic biofeedback
36 therapy can improve the active range of motion of shoulder and wrist joints after stroke.
37 Authors concluded that in this meta-analysis, electromyographic biofeedback therapy
38 intervention can improve upper and lower limb function in patients with stroke. Short-term
39 (less than one month) improvement after electromyographic biofeedback therapy was
40 supported, while evidence for long-term (more than one month) benefits was lacking.
41 Range of motion in the glenohumeral and wrist joints were improved. Stronger evidence

1 for individualized parameters, such as optimal treatment parameters and intervention
 2 period, is needed in the future.

4 **Other Conditions**

5 Biofeedback has been proposed as a treatment modality for numerous other conditions
 6 including: alcohol and drug abuse, anxiety disorders, asthma, autism spectrum disorders,
 7 cancer pain and symptoms, cardiovascular disease, cerebral palsy, acute and chronic back
 8 pain, chronic prostatitis, cystic fibrosis, epilepsy, fibromyalgia, functional dyspepsia, heart
 9 failure, hypertension, hyperhidrosis, knee osteoarthritis, labor pain, pervasive
 10 developmental disorders, posttraumatic stress disorder (PTSD), Raynaud’s syndrome,
 11 recurrent urinary tract infection, reflex sympathetic dystrophy or complex regional pain
 12 syndrome, rheumatoid arthritis, spastic torticollis, temporomandibular disorders, tinnitus,
 13 type 2 diabetes mellitus, upper limb pain, vulvodynia and whiplash. However, the evidence
 14 in the published peer-reviewed scientific literature does not support the efficacy of
 15 biofeedback for the treatment of these conditions. Overall, there is a lack of randomized
 16 controlled trials using sufficient sample sizes, comparing biofeedback to established
 17 therapeutic modalities (e.g., pharmacotherapy, behavior therapy) with long-term follow-
 18 ups. Patient selection criteria for biofeedback for these conditions have not been established
 19 and reported sustained benefit past the treatment period are lacking (Hayes Inc., 2016;
 20 McKee and Moravec, 2010; Yilmaz, et al., 2010; Glasscoe and Quittner, 2008; McGinnis,
 21 et al., 2005).

23 Cancer

24 Patients undergoing oncologic therapy experience persistent pain, fatigue, anxiety, and side
 25 effects from chemotherapy. In addition to pharmacotherapy, biofeedback has been
 26 proposed as an adjunct treatment modality for this patient population. However, there is
 27 insufficient evidence in the published peer-reviewed literature to support biofeedback for
 28 the management of cancer. There have been a limited number of studies with small patient
 29 populations ($n=12-81$), short-term follow-ups (e.g., 3 months) and in some studies, lack of
 30 a control group. Most studies were conducted prior to 2000. Biofeedback has not been
 31 shown to be effective in reducing cancer pain or chemotherapy side effects.

32
 33 The American Cancer Society (2015) stated biofeedback under the supervision of a
 34 licensed biofeedback technician is a non-medical treatment that is sometimes used to help
 35 people relax and cope with pain and is typically used with other pain-relief methods. In
 36 their supportive care guideline on adult cancer pain, the National Comprehensive Cancer
 37 Network (NCCN) lists consideration of biofeedback as an option for psychological support
 38 (NCCN, 2021).

40 Chronic Neck, Upper Back and Low Back Pain

41 Biofeedback has been proposed as a treatment modality for chronic back pain to help
 42 relieve the tension in the back muscles and alleviate pain. Henschke et al. (2010) conducted

1 a systematic review of 30 randomized controlled trials (RCTs) that investigated behavioral
 2 treatment (e.g., biofeedback) for low back pain. There was low quality evidence (3 RCTs;
 3 $n=64$) that EMG biofeedback was more effective than waiting list or progressive relaxation
 4 (1 RCT; $n=24$).

5
 6 Ostelo et al. (2005) conducted a systematic review of the literature to determine if
 7 behavioral treatments (including biofeedback) for nonspecific chronic low back pain
 8 (CLBP) were more effective than other treatments compared to waiting-list controls
 9 (WLC). Twenty-one randomized controlled trials met inclusion criteria. CLBP was defined
 10 as back pain that persisted for 12 weeks or more. Studies of individuals with CLBP caused
 11 by pathological entities including infection, neoplasm, fracture, osteoporosis, and
 12 rheumatoid arthritis (RA) were excluded. The investigators reported that there is moderate
 13 evidence (3 studies, $n=88$) that there is no significant difference between EMG biofeedback
 14 and WLC on behavioral outcomes in the short term. There is conflicting evidence (two
 15 studies, $n=60$) on the effectiveness of EMG biofeedback versus WLC on general functional
 16 status. There is limited evidence (1 study, $n=28$) of EMG biofeedback for a small short-
 17 term positive effect on back-specific functional status. Cognitive behavioral treatment
 18 (CBT) was compared to EMG biofeedback in one study ($n=28$), which found no
 19 differences in the groups for pain or any behavioral outcome measures either in the short
 20 or long term. A combination of CBT and EMG biofeedback compared to WLC (4 studies,
 21 $n=134$) found strong evidence for a short-term, positive effect on pain intensity, but no
 22 differences on behavioral outcomes or general functional status in the short term compared
 23 to WLC. More research is needed to determine what types of behavioral interventions are
 24 most effective for pain relief and which patients would benefit most from a specific type
 25 of behavioral treatment. The investigators stated no determination could be made from this
 26 review as to whether patients should be referred to behavioral treatment programs or to
 27 active conservative treatment programs.

28
 29 The American College of Physicians (ACP) (2017) developed guidelines based on an
 30 evidentiary review of the literature to provide clinical recommendations on noninvasive
 31 treatment of low back pain. ACP recommended that select nonpharmacologic treatment be
 32 used initially. Low quality evidence reported that electromyography biofeedback reduced
 33 pain compared to wait list but there was no effect on function.

34
 35 The American Society of Anesthesiologist Task Force on Chronic Pain Management and
 36 the American Society of Regional Anesthesia and Pain Medicine (2010) stated that
 37 psychological treatment including biofeedback “may be used as part of a multimodal
 38 strategy for low back pain and for other chronic pain conditions.”

39
 40 Eslamian et al. (2020) sought to determine the differences between clinical effects of
 41 electroacupuncture and biofeedback therapy in addition to conventional treatment in
 42 patients with cervical myofascial pain syndrome (MPS). Fifty patients ($N=50$) aged 25-55

1 years of both sexes with chronic neck pain diagnosed with MPS (characterized by trigger
 2 points within taut bands) were randomly assigned to 2 equal groups of 25 individuals. The
 3 patients in electroacupuncture group were treated with standard acupuncture and
 4 concomitant electrical stimulation; those in biofeedback group received visual
 5 electromyography biofeedback therapy for muscle activity and relaxation. Both groups
 6 received the intervention 2 times a week for a total of 6 sessions. Basic exercise training and
 7 medicines were administered for all the patients. Authors concluded that both
 8 electroacupuncture and biofeedback therapies were found to be effective in management of
 9 MPS when integrated with conventional treatment. However, intergroup differences
 10 showed priority of acupuncture in some parameters vs biofeedback. Thus,
 11 electroacupuncture seems to be a better complementary modality for treatment of MPS in
 12 the neck and upper back area. Campo et al. (2021) evaluated the safety and efficacy of
 13 electromyographic and pressure biofeedback on pain, disability, and work ability in adults
 14 with neck pain. Authors noted that moderate-quality evidence suggests biofeedback has a
 15 moderate effect on reducing short-term disability and a small effect on reducing
 16 intermediate-term disability. Biofeedback had no effect on pain or work ability in the short-
 17 and intermediate-term (low-to moderate-quality evidence). Authors conclude that
 18 biofeedback appears to have a small-to-moderate effect on reducing neck pain disability in
 19 the short- and intermediate-term, but no effect on pain or work ability. More trials reporting
 20 adverse events and comparing biofeedback to placebo are needed.

21
 22 Wagner et al. (2021) evaluated evidence from the literature with a focus on the effect of
 23 biofeedback on pain reduction, overall symptom relief, physiological parameters and quality
 24 of life. Out of 651 studies, 37 quantitative studies of primary research evaluating pelvic pain
 25 conditions in male and female adults and children were included. They covered biofeedback
 26 interventions on anorectal disorders, chronic prostatitis, female chronic pelvic pain
 27 conditions, urologic phenotypes in children and adults and a single study on low back pain.
 28 For anorectal disorders, several landmark studies demonstrate the efficacy of biofeedback.
 29 For other subtypes of chronic pelvic pain conditions there is tentative evidence that
 30 biofeedback-assisted training has a positive effect on pain reduction, overall symptoms
 31 relief and quality of life. Authors conclude that for certain indications, biofeedback has been
 32 confirmed to be an effective treatment.

33 34 Epilepsy

35 In an effort to reduce abnormal brain waves and seizure frequency, biofeedback has been
 36 proposed for the treatment of epilepsy. Ramaratnam et al. (2008) conducted a meta-analysis
 37 of psychological treatments, including biofeedback, for epilepsy. Randomized and quasi-
 38 randomized studies were analyzed. Outcomes included quality of life and seizure frequency.
 39 Of the two trials including relaxation and behavioral therapy, one reported positive results
 40 by decreasing anxiety and enhancing adjustment. Another study of galvanic skin response
 41 reported reduction in seizure activity. A study using EEG biofeedback improved cognitive
 42 and motor functions in subjects with the greatest seizure reduction. The studies were deficient

1 in methodology and due to the limited number of studies, the evidence wasn't considered
 2 reliable. In their clinical guideline for diagnosing and managing epilepsy in children and
 3 adults, NICE (2016) stated that psychological interventions, including biofeedback, may be
 4 used as an adjuvant therapy to anti-epileptic drugs (AED) to improve quality of life in adults
 5 who are not receiving optimal benefit from AED. However, psychological interventions have
 6 not proven to affect seizure frequency and are not an alternative to pharmacological
 7 treatment.

9 Fibromyalgia

10 Biofeedback has been proposed for the treatment of fibromyalgia in an effort to facilitate
 11 and train an individual in maintaining a state of relaxation and decreased pain. In a
 12 randomized controlled trial, Babu et al. (2007) compared EMG biofeedback ($n=15$) to
 13 sham ($n=15$) and reported a significant decrease in pain and the number of tender points in
 14 the treatment group. However, there were no significant differences in the fibromyalgia
 15 impact questionnaire, or the six-minute walk test. Both groups experienced a significant
 16 decrease in FIQ and visual analogue scale, but the decreases were greater in the
 17 biofeedback group.

18
 19 Reneau (2020) reports that fibromyalgia (FM) is associated with debilitating pain and a
 20 reduced heart rate variability (HRV), reflecting decreased emotional adaptability and
 21 resistance to stress. Given this, they postulate that heart rate variability biofeedback
 22 (HRVB) may be effective in improving HRV, thus increasing stress resistance and
 23 emotional adaptability and reducing pain. They reviewed 22 articles and included six in
 24 this review. Five reported HRVB as a treatment for chronic pain, and one for FM pain.
 25 Overall, the articles in this review support the claim that HRVB is related to decreased
 26 pain. The researchers evaluated five HRVB programs, three on handheld devices and two
 27 on desktop computers. Authors conclude that despite the reviewed studies having
 28 methodological flaws, HRVB is a promising treatment for chronic pain. Larger,
 29 randomized controlled studies are needed to thoroughly evaluate the relationship between
 30 HRVB and FM pain.

32 Functional Dyspepsia (FD)

33 Because low vagal tone may be a mediating mechanism by which psychological factors
 34 induce dyspepsia in FD, it has been hypothesized that biofeedback may be a helpful
 35 treatment modality by enhancing vagal tone, leading to improvement in parasympathetic
 36 activity and drinking capacity. In a randomized controlled trial ($n=40$), patients were
 37 allocated to investigation, information, and biofeedback with breathing exercises or to
 38 investigation and information only. Drinking capacity and quality of life significantly
 39 improved ($p=0.02$, $p=0.01$, respectively) following biofeedback, but an improvement in
 40 baseline vagal tone was not noted (Hjelland et al., 2007).

1 Hypertension

2 Because of its potential to decrease stress and enhance relaxation, biofeedback has been
3 proposed for the treatment of hypertension. Greenhalgh et al. (2009) conducted a systematic
4 review to determine the clinical benefits and long-term effects of biofeedback for the
5 treatment of essential hypertension in adults. Forty-one studies, including 36 randomized
6 controlled trials ($n=1660$), met inclusion criteria. Twenty-one trials used biofeedback only
7 and 15 trials used biofeedback with other treatment modalities. No meta-analysis was
8 completed due to the poor reporting quality of the studies and the large degree of
9 heterogeneity of treatments and comparators. Overall, the trials included small patient
10 populations, no follow-up or follow-up less than 12 months. Other limitations of the studies
11 included the variation in interventions, inconsistencies in measurement of outcomes, and
12 the conflicting and variable results. No consistent short- or long-term benefits in the control
13 of hypertension were seen when biofeedback was compared to pharmacotherapy, sham
14 biofeedback, no intervention, or other behavioral therapies (e.g., relaxation, hypnosis,
15 meditation, stress education).

16
17 Nakao et al. (2003) conducted a meta-analysis of 22 randomized controlled studies of
18 essential hypertensive patients ($n=905$). Biofeedback intervention resulted in blood
19 pressure reductions that were greater by 7.3 millimeters (mm) of mercury (Hg) systolic and
20 5.8 mmHg diastolic compared to nonintervention controls (such as clinical visits or self-
21 monitoring of blood pressure). Compared to sham or nonspecific behavioral intervention
22 controls, the net reductions in systolic and diastolic blood pressures by biofeedback
23 intervention were 3.9 mmHg and 3.5 mmHg, respectively. Reviewers were unable to
24 determine whether biofeedback itself had an antihypertensive effect beyond the general
25 relaxation response because biofeedback was only found to be superior to sham or
26 nonspecific behavioral intervention when combined with other relaxation techniques. The
27 investigators concluded that large, randomized controlled trials are needed to determine
28 whether biofeedback itself has an antihypertensive effect beyond the general relaxation
29 response.

30
31 An evidence-based statement by the American Heart Association (AHA) included the
32 investigation of biofeedback as an alternative therapy for lowering blood pressure (BP).
33 AHA noted that the mechanisms responsible for BP lowering by biofeedback are
34 incompletely described. Some evidence favors alteration in the autonomic nervous system
35 balance. Systematic reviews and meta-analysis that have investigated biofeedback for this
36 indication have reported conflicting results. Studies have been limited by “short duration,
37 small sample sizes, difficulties with blinding, and significant heterogeneity when trial data
38 were combined”. Also, some meta-analyses have combined multiple complementary
39 medicine techniques in their analyses, making it difficult to assess the impact of biofeedback
40 alone. Due to the paucity of data, recommendation for using a specific biofeedback method
41 could not be made. Overall, no significant adverse effects were reported. Based on this
42 review, AHA stated that biofeedback may be considered in clinical practice to lower BP.

1 This is a Class IIB, Level of Evidence B, recommendation meaning that the
2 usefulness/efficacy of biofeedback is less well established and there is greater conflicting
3 evidence from randomized controlled trials or meta-analysis (Brooke et al., 2013).

4
5 Elavally et al. (2020) investigated the effect of nurse-led home-based biofeedback
6 intervention on the blood pressure levels among patients with hypertension. Uncomplicated
7 primary hypertension outpatients were randomly assigned as study group ($n = 173$) and
8 control group ($n = 173$) at a tertiary care hospital. Sociodemographic, clinical, and outcome
9 variables [the baseline blood pressure and galvanic skin response (GSR)] were collected.
10 Study group patients were given four teaching sessions of abdominal breathing-assisted
11 relaxation facilitated by galvanic skin response (GSR) biofeedback. Daily home practice
12 was encouraged and monitored to measure the effects on blood pressure and GSR at the end
13 of the 1st, 2nd, and 3rd month of intervention. The study group participants showed significant
14 decrease in mean (SD) systolic and diastolic blood pressure. In contrast, control group
15 participants had a mild increase in the mean systolic and diastolic blood pressure values
16 from pretest to posttests. GSR showed a significant increase from 559.63 (226.33) to 615.03
17 (232.24), ($F = 80.21$) from pretest to posttest III. Authors concluded that use of home-based
18 biofeedback-centered behavioral interventions enabled BP reduction among hypertensive
19 patients. Further studies should use biochemical markers of sympathetic nervous system
20 activity to endorse this home-based chronic illness intervention.

21
22 Burlaco et al. (2021) aimed to systematically review the literature to investigate the impact
23 of HRV modulation through HRV-biofeedback on clinical outcomes in patients with CVD.
24 Patients in the HRV-biofeedback group had significantly lower rates of all-cause
25 readmissions than patients who received psychological education. Heart failure following
26 HRV-biofeedback displayed an inverse association with stress and depression. HRV-
27 biofeedback had beneficial effects on different cardiovascular diseases documented in
28 clinical trials, such as arterial hypertension, heart failure, and coronary artery disease.
29 Fournié et al. (2021) performed a review according to eligibility criteria including adult
30 chronic patients, HRVB as main treatment with or without control conditions, and
31 psychophysiological outcomes as dependent variables. In total, 29 articles were included.
32 Reported results showed the feasibility of HRVB in chronic patients without adverse effects.
33 Significant positive effects were found in various patient profiles on hypertension and
34 cardiovascular prognosis, inflammatory state, asthma disorders, depression and anxiety,
35 sleep disturbances, cognitive performance, and pain, which could be associated with
36 improved quality of life. Improvements in clinical outcomes co-occurred with
37 improvements in heart rate variability, suggesting possible regulatory effect of HRVB on
38 autonomic function. Authors concluded that HRVB could be effective in managing patients
39 with chronic diseases.

1 Irritable Bowel Syndrome (IBS)

2 The clinical guideline on the management of irritable bowel syndrome (IBS) published by
 3 NICE (2008; updated 2017) stated that reviews of biofeedback suggested a positive effect
 4 on the control of IBS symptoms, but evidence was limited and not sufficient to make
 5 recommendations. A systematic review of the literature identified four randomized
 6 controlled trials that met inclusion criteria. One study compared biofeedback to counseling
 7 and three studies evaluated multi-component therapy (a combination of educational
 8 information, progressive relaxation therapy, thermal biofeedback treatment and training in
 9 stress coping strategies) compared to symptom monitoring or attention placebo controls.
 10 There was limited, weak evidence to show a statistically significant improvement in global
 11 symptoms for biofeedback and reduction in diarrhea compared to symptom monitoring.
 12 No significant differences between biofeedback and attention placebo or between symptom
 13 monitoring and attention placebo were reported, but there was much uncertainty due to
 14 wide confidence intervals. There was insufficient evidence to determine the effects of
 15 biofeedback on pain, bloating and constipation. A Cochrane Review by Goldenberg et al.
 16 (2019) also concluded that there is currently not enough evidence to assess whether
 17 biofeedback interventions are effective for controlling symptoms of IBS.

18
 19 Labor Pain

20 In a systematic review, Jones, et al. (2012) summarized the evidence on the efficacy and
 21 safety of non-pharmacological and pharmacological interventions to manage labor pain.
 22 Fifteen Cochrane reviews ($n=255$ trials) and three non-Cochrane reviews ($n=55$ trials) met
 23 inclusion criteria. There was insufficient evidence from four randomized controlled trials
 24 ($n=201$) to determine if biofeedback was more effective than placebo or other interventions
 25 for labor pain management.

26
 27 Barragán et al. (2011) conducted a systematic review of randomized controlled trials to
 28 evaluate the efficacy of biofeedback in the management of labor pain. Four trials ($n=186$)
 29 met inclusion criteria and primarily used EMG biofeedback. There were no significant
 30 differences between biofeedback and the control groups in terms of assisted vaginal birth,
 31 caesarean section, augmentation of labor and the use of pharmacological pain relief. Some
 32 studies reported that EMG biofeedback may have had some positive effects early in labor,
 33 but as labor progressed there was a need for additional pharmacological analgesia.

34
 35 Knee Conditions

36 Richard et al. (2017) conducted a systematic review of the literature to evaluate the
 37 effectiveness of real-time biofeedback as a method for gait retraining to reduce knee
 38 adduction movement (KAM) in patients with knee osteoarthritis (KOA). Twelve
 39 uncontrolled studies met inclusion criteria. Seven studies used healthy subjects and five
 40 studies enrolled patients with KOA. Because of the lack of studies reporting between-group
 41 effects, this review focused on within-group effects. Within-group standardized mean
 42 differences (SMDs) for reduction of KAM in healthy controls ranged from 0.44 to 2.47 and

1 from 0.29 to 0.37 in patients with KOA. In patients with KOA, improvements were reported
2 in pain and function, with SMDs ranging from 0.55 to 1.16. Limitations of the studies
3 included: small number of studies that enrolled KOA patients; small patient populations;
4 heterogeneity of study design, methods of feedback and number of training sessions (many
5 studies only reported on one session); short-term follow-ups (e.g., one month); and lack of
6 a comparator and control group. The authors noted that there was insufficient information
7 to conclude the optimal method of feedback delivery or the optimal instructions for subjects
8 to achieve KAM reductions. Additional studies with large patient populations and long-
9 term follow-up are needed to support biofeedback for this indication.

10
11 Wasielewski et al. (2011) conducted a systematic review of eight randomized controlled
12 trials ($n=319$ subjects) to evaluate the effectiveness of electromyographic biofeedback
13 (EMGB) of the quadriceps femoris muscle for the treatment of knee conditions. Diagnosis
14 included patellofemoral pain syndrome (two trials; $n=86$), anterior cruciate ligament
15 reconstruction (two trials; $n=52$), arthroscopic surgery (two trials; $n=91$) or osteoarthritis
16 (two trials; $n=90$). EMGB appeared to benefit short-term postsurgical pain or quadriceps
17 strength in three out of the four postsurgical investigations but was reported ineffective for
18 chronic knee conditions including patellofemoral pain and osteoarthritis. Limitations of the
19 studies included small heterogeneous patient populations, variability in interventions and
20 outcomes, and poor methodology. The authors stated that the results should be viewed with
21 caution due to the limited data and poor studies.

22
23 Karaborklu Argut et al. (2021) presented an evidence-based overview of the current
24 utilization and the effectiveness of therapeutic Electromyographic Biofeedback (EMG-BF)
25 in rehabilitation after orthopedic knee surgeries. Eight RCTs investigating effectiveness of
26 the EMG-BF in rehabilitation after orthopedic knee surgeries were identified. Most of the
27 included studies reported that EMG-BF was more effective compared to home exercises,
28 standard rehabilitation program or electrical stimulation for improving quadriceps strength
29 or activation. Besides, EMG-BF was revealed positive results in functional assessments
30 except gait velocity and IKDC. Only two studies reported knee ROMs were significantly
31 improved in favor of EMG-BF. Authors concluded that EMG-BF seems to control pain
32 and improve quadriceps femoris strength and functionality. However, the results are
33 inconclusive regarding knee ROM. Although available high-quality evidence is limited,
34 EMG-BF might be a part of the rehabilitation after knee surgeries.

35
36 Xie et al. (2021) aimed to determine whether EMG-biofeedback is effective for improving
37 the range of motion (ROM), physical function, and pain relief in patients after knee surgery.
38 Randomized controlled trials (RCTs) assessing the effect of EMG-biofeedback after any
39 knee surgery were retrieved. This review identified 773 unique studies, and six RCTs were
40 in the final meta-analysis. EMG-Biofeedback treatment has a significant difference
41 compared to other rehabilitation therapy in knee ROM improving). Moreover, there was
42 no significant difference in pain and physical function. The results illustrate that EMG-

1 biofeedback can improve knee ROM in patients after knee surgery. However, it is not
2 superior to other rehabilitation methods for pain relief and physical function improvement.

3
4 Glatke et al. (2022) completed a systematic review on rehabilitation after ACL
5 reconstructive surgery. A total of 824 articles from 2012 to 2020 were identified using
6 multiple search engines. Fifty Level-I or II studies met inclusion criteria. Authors stated
7 that electromyography biofeedback may help to regain muscular function.

8 9 Nonneuropathic Voiding Disorders

10 Fazeli et al. (2014) conducted a systematic review and meta-analysis to evaluate
11 biofeedback for the treatment of nonneuropathic daytime voiding disorders (NVD) in
12 children. The hallmark of nonneuropathic voiding disorders is lower urinary tract
13 symptoms with or without urinary incontinence. Five randomized controlled trials
14 ($n=487$) met inclusion criteria and four studies ($n=382$) were included in the meta-
15 analysis. At six months follow-up, there were no significant differences in the number of
16 cases with resolved incontinence, mean maximum urinary flow rate or the likelihood of
17 urinary tract infection with biofeedback vs. control group without biofeedback. The data
18 does not support biofeedback for the treatment of this subpopulation.

19
20 Qi et al. (2022) assessed the efficacy of biofeedback treatment for children’s non-
21 neurogenic voiding dysfunction (NVD), which is a syndrome characterized by lower
22 urinary tract symptoms (LUTs) because of the inability to relax the external sphincter.
23 Patients with NVD always suffer from urinary tract infections (UTI), incontinence,
24 constipation. Fifteen studies and 1274 patients were included in the systemic review,
25 seven RCTs and 539 patients were included in meta-analysis. Meta-analysis showed
26 efficacy of biofeedback treatment in following aspects, (1) relieving UTI, (2) reducing
27 PVR, (3) increasing maximum urine flow rate and average urine flow rate, (4) relieving
28 constipation, (5) improving abnormal voiding pattern and abnormal EMG during voiding.
29 The improvement of UTI symptoms, maximum urine flow rate and average urine flow
30 rate took a longer time (12 months). In terms of daytime incontinence, nighttime
31 incontinence, no significant difference was found between biofeedback treatment and
32 standard urotherapy. The qualitative analysis showed that biofeedback treatment was
33 beneficial for NVD. Authors concluded that compared with standard urotherapy,
34 biofeedback treatment is effective for some symptoms, such as UTI and constipation, and
35 can improve some uroflowmetric parameters, such as PVR. Biofeedback treatment seems
36 to have a better long-term effect.

37 38 Raynaud’s Syndrome

39 Proponents of biofeedback for Raynaud’s state that using thermal biofeedback to produce
40 vasodilation may help relieve the severity and frequency of attacks. Malenfant et al. (2009)
41 conducted a systematic review and meta-analysis of randomized controlled trials on
42 complementary and alternative medicine, including biofeedback ($n=5$ studies), for the

1 treatment of Raynaud’s phenomenon. The outcomes of the biofeedback studies ($n=15$ –
 2 155) favored sham therapy over biofeedback ($p<0.02$). There were no significant
 3 differences in frequency or duration or severity of Raynaud’s attacks. The authors
 4 concluded that biofeedback is not an effective therapeutic intervention for the treatment of
 5 Raynaud’s.

6 7 Recurrent Urinary Tract Infection

8 Minardi et al. (2010) conducted a randomized controlled trial to evaluate the efficacy of
 9 uroflowmetry biofeedback and pelvic floor relaxation biofeedback in women ($n=86$) with
 10 more than a three-year history of recurrent urinary tract infections (UTI) (i.e., three or more
 11 symptomatic episodes per year) and dysfunctional voiding. The authors defined
 12 dysfunctional voiding as an abnormally learned spectrum of voiding behavior in
 13 neurologically normal individuals. The women were randomized to one of four groups:
 14 group 1 ($n=24$), uroflowmetry biofeedback; group 2 ($n=21$), biofeedback training of the
 15 pelvic floor muscles; group 3 uroflowmetry biofeedback combined with biofeedback
 16 training of the pelvic floor muscles; and group 4 no treatment. Patients also received
 17 antibiotics during the study when indicated. At the three-, six- and 12-month follow-ups
 18 there were significant improvements ($p<0.05$, each), which remained stable, in all of the
 19 following outcome measures: storage and emptying symptoms, mean flow rate, flow time,
 20 voiding and volume; overall voiding pattern; post-void residual urine; mean opening
 21 detrusor pressure and detrusor pressure at maximum flow; and the prevalence of UTI. No
 22 significant improvements were seen in the untreated group. At 24 months in the treated
 23 groups, the storage and emptying symptoms and voiding patterns were similar to baseline
 24 values in 55% of patients, and the incidence of UTIs was similar in 45% of patients. The
 25 authors noted that this was the first study of pelvic floor therapy for the treatment of
 26 recurrent UTIs in women. Limitations of the study include the small patient population,
 27 short-term follow-up and the number of patients lost to follow-up (142 were originally
 28 enrolled).

29 30 Rheumatoid Arthritis (RA)

31 Biofeedback has been proposed for the treatment of RA to help alleviate tension, stress,
 32 anxiety, insomnia, and other symptoms that may cause acute flair-ups and/or enhance
 33 arthritic pain. Astin et al. (2002) conducted a systematic review of the literature to
 34 investigate the effect of psychological interventions (including biofeedback) on patients
 35 with RA. Outcome measures included functional ability, pain, tender joints, psychological
 36 status, and coping ability. Twenty-five randomized controlled trials ($n=1676$) met inclusion
 37 criteria. Because separate results by type of intervention (i.e., relaxation, biofeedback,
 38 CBT) were not identified, the authors could not report which psychological interventions
 39 or combinations of interventions were most effective and for which types of patients.
 40 Methodological flaws in the studies included: inadequate description of controls and the
 41 effect sizes were not always consistent with signs of confidence intervals. The authors

1 concluded that more research was needed to determine which treatments may be of benefit
2 for patients with RA.

3 Sleep Bruxism

4 Biofeedback has been proposed as a treatment option for sleep bruxism, a sleep-related
5 disorder characterized by teeth grinding or jaw clenching. In a systematic review of seven
6 randomized controlled trials ($n=240$), Wang et al. (2014) concluded that the evidence did
7 not support biofeedback for this condition. Meta-analysis showed no significant
8 differences between biofeedback and controls ($p=0.26$). The studies were limited by the
9 heterogeneity of the biofeedback modalities (i.e., auditory, electrical, and visual feedback)
10 and regimens, and the use of various control modalities (e.g., splint, occlusal adjustment)
11 and outcome measures. The classification of risk of bias was moderate to high.
12 Jokubauskas and Baltrušaitytė (2018) updated the review published by Wang et al in 2014.
13 The review focuses on the most recent literature on management of sleep bruxism (SB)
14 with biofeedback. Six articles of 2320 identified citations involving 86 adult participants
15 were included in the qualitative synthesis. Of them, 4 were randomized controlled trials
16 (RCTs) and 2 were uncontrolled before-after studies. Different feedback modalities
17 (electrical, auditory, and vibratory stimulus) were investigated. The meta-analysis
18 indicated a non-significant difference in electromyographic-measured SB episodes per
19 hour after one night of contingent electrical stimulation (CES) compared with placebo
20 control, yet a significant difference was shown after five nights of CES. The quality of
21 evidence was graded from low to moderate, due to imprecision and inconsistency between
22 studies. Authors concluded that one of the biofeedback modalities, CES, is effective in
23 reducing SB-related motor activities after a short-term treatment period. However,
24 evidence of long-term effects is lacking. Further longitudinal studies with larger samples
25 are necessary to acknowledge the clinical application of biofeedback. Bussadori et al.
26 (2020) mapped the evidence from systematic reviews (SR), examining the effects of
27 interventions to improve chronic pain related to bruxism. There was no difference in pain
28 and bruxism frequency between biofeedback therapy and an inactive control group.
29 Authors concluded that there was no evidence was provided to support the
30 recommendation of biofeedback therapy and drug therapy. There is still a need for more
31 methodologically rigorous randomized clinical trials (RCT) to be conducted on the efficacy
32 and safety of different therapies for SB.
33
34

35 Temporomandibular Disorders (TMD)/Temporomandibular Joint (TMJ) Disorders

36 As in other chronic pain conditions, biofeedback has been investigated to determine if
37 relaxation and relief of stress and tension following biofeedback would alleviate the pain
38 of TMD. A systematic review by Medlicott and Harris (2006) included seven randomized
39 controlled trials which evaluated the effectiveness of relaxation training or biofeedback in
40 the management of TMD. From the review of these studies, the authors stated that
41 programs involving relaxation techniques and biofeedback, EMG training, and
42 proprioceptive reeducation may be more effective than placebo or occlusal splints in

1 decreasing pain and increasing total vertical opening in patients with acute or chronic
 2 myofascial or muscular TMD. However, it was noted by the authors that “these
 3 recommendations should be viewed cautiously.”

4
 5 In a 2005 systematic review, Crider et al. reported on six randomized controlled trials
 6 regarding the efficacy of biofeedback-based therapy for TMD. Two trials included surface
 7 electromyographic (SEMG) training of masticatory muscles; two combined SEMG with
 8 cognitive-behavioral therapy (CBT); and two involved biofeedback-assisted relaxation
 9 training (BART). The review determined the extent that each intervention met treatment
 10 efficacy criteria established by the Association for Applied Psychophysiology and
 11 Biofeedback (AAPB). Based upon the review of the studies, the authors stated that SEMG
 12 training and BART were “probably an efficacious treatment” and SEMG with CBT is an
 13 efficacious treatment. They recommended additional studies to identify specific treatment
 14 combinations.

15
 16 Yao et al. (2024) explored the comparative effectiveness of available therapies for chronic
 17 pain associated with temporomandibular disorders (TMD). 233 trials proved eligible for
 18 review, of which 153-enrolling 8713 participants and exploring 59 interventions or
 19 combinations of interventions-were included in network meta-analyses. All subsequent
 20 effects refer to comparisons with placebo or sham procedures. Effects on pain for eight
 21 interventions were supported by high to moderate certainty evidence. The three therapies
 22 probably most effective for pain relief were cognitive behavioral therapy (CBT) augmented
 23 with biofeedback or relaxation therapy, therapist-assisted jaw mobilization, and manual
 24 trigger point therapy. Five interventions were less effective, yet more effective than
 25 placebo: CBT, supervised postural exercise, supervised jaw exercise and stretching,
 26 supervised jaw exercise and stretching with manual trigger point therapy, and usual care
 27 (such as home exercises, self-stretching, reassurance). Moderate certainty evidence showed
 28 four interventions probably improved physical functioning: supervised jaw exercise and
 29 stretching, manipulation, acupuncture, and supervised jaw exercise and mobilization. The
 30 evidence for pain relief or physical functioning among other interventions, and all evidence
 31 for adverse events, was low or very low certainty.

32 33 Tinnitus

34 Weise et al. (2008) conducted a randomized controlled trial to compare the effects of
 35 biofeedback ($n=63$) to a wait-list control group (WLG) ($n=67$) in patients with chronic
 36 tinnitus (i.e., more than six months duration). Patients underwent 12, one-hour EMG
 37 biofeedback sessions with tinnitus-specific cognitive– behavioral therapy (CBT) (e.g.,
 38 directing attention away from tinnitus, relapse prevention) over a three-month period. Final
 39 follow-up occurred six months following cessation of treatment. Following treatment,
 40 intention-to-treat statistical analysis based on results of interviews and self-reported
 41 questionnaires showed significantly less emotional and cognitive distress; less intrusive
 42 tinnitus, less auditory perceptual difficulties, less sleep disturbances and fewer somatic

1 complaints in the biofeedback group ($p < 0.01$ for each). No significant differences were
 2 reported in the WLG. Compared to pretreatment and the WLG, patients in the biofeedback
 3 group reported fewer feelings of helplessness, increased feelings of resourcefulness, fewer
 4 catastrophizing self-statements, and more helpful coping self-statements. However, no
 5 significant effect was found for depressive and general psychopathological symptoms.
 6 Following a waiting period, 52 WLG patients received biofeedback and showed a
 7 significant improvement in outcomes. The authors noted that the study was limited by the
 8 WLG instead of an active treatment control group (CBT without biofeedback). Other
 9 limitations of the study are the short-term follow-up, and the dropout rate ($n=26$).

11 Upper Limb Pain

12 A limited number of studies have been conducted to determine if the muscle relaxation
 13 effect of biofeedback could help alleviate the pain of repetitive strain in the upper limbs.
 14 Karjalainen et al. (2004) conducted a systematic review of the literature to determine the
 15 effectiveness of biopsychosocial rehabilitation for upper-limb repetitive strain injuries
 16 among working-age adults. Two prospective randomized studies ($n=80$) met inclusion
 17 criteria, and both were considered to be of low quality due to methodological flaws. Studies
 18 which included EMG biofeedback as the only component of physiological rehabilitation
 19 were excluded. The authors concluded that there were no differences in effect between
 20 applied relaxation, EMG biofeedback plus applied relaxation, and waiting-list controls
 21 after eight weeks and six months of follow-up.

23 Vulvodynia

24 Following the hypothesis that vulvodynia, also called vulvar vestibulitis or vulvar
 25 vestibulodynia, may be due to an abnormality in pelvic floor muscle tone, biofeedback has
 26 been investigated as a treatment modality for muscle training. In a randomized controlled
 27 study, Bergeron et al. (2001) prospectively evaluated and compared EMG biofeedback (12-
 28 week trial), group cognitive-behavioral (12-week trial), and vestibulectomy in the
 29 treatment of dyspareunia resulting from vulvar vestibulodynia. Seventy-eight women were
 30 randomly assigned to one of the three treatment regimens. Following treatment, all groups
 31 reported statistically significant reductions on pain measures up to the six-month follow-
 32 up. The vestibulectomy group was significantly more successful than the other two groups,
 33 reporting a 70% mean reduction in pain and a greater quality of life improvement. The
 34 biofeedback participants experienced a higher six-month dropout rate, reflecting patient
 35 difficulty following through with the long-term and repetitive treatment protocols. The
 36 authors stated that the results should be interpreted with caution because there were
 37 significantly more participants in the vestibulectomy condition who refused to undergo the
 38 treatment they had been randomized to, as compared to participants in the two other
 39 treatment conditions”

1 The American Society for Colposcopy and Cervical Pathology’s (ASCCP) vulvodynia
 2 guideline update (Stockdale, et al., 2013) stated that biofeedback may be used in the
 3 treatment of vulvodynia to aid patients in confronting and reducing pain.

4
 5 In a 2016 updated Committee Opinion on persistent vulvar pain, the American Congress
 6 of Obstetricians and Gynecologists (ACOG) and American Society for Colposcopy and
 7 Cervical Pathology (ASCCP) recommendations and conclusions stated that women with
 8 vulvodynia should be assessed for pelvic floor dysfunction. Biofeedback and/or physical
 9 therapy, including pelvic floor physical therapy can be used to treat localized and
 10 generalized vulvar pain especially if there is concomitant vaginismus.

11
 12 Nascimento et al. (2024) assessed the efficacy of physiotherapy for vulvodynia. A total of
 13 2,274 articles were retrieved. Seven studies met the criteria and were included in a
 14 systematic review, which included a total of 477 patients. The interventions included were
 15 electromyography biofeedback (n = 2), transcutaneous electrical nerve stimulation (n =
 16 1), transcranial direct current stimulation (n = 1), low-intensity shockwave (n = 1),
 17 physiotherapy treatment (n = 1), and pelvic floor exercise with behavioral modification (n = 1).
 18 All studies evaluated pain reduction, 5 evaluated sexual function, and 2 evaluated
 19 quality of life. All interventions were effective for the main outcomes; only the transcranial
 20 direct current stimulation intervention showed no significant difference when compared
 21 with the placebo or sham group. Three studies presented a high risk of bias due to the lack
 22 of blinding. Authors concluded that the studied interventions (electromyography
 23 biofeedback, transcutaneous electrical nerve stimulation, shockwave, physiotherapy, and
 24 pelvic floor exercise) seem to improve pain, sexual function, and quality of life. However,
 25 the heterogeneity of the studies prevented meta-analysis. In addition, well-designed trials
 26 are needed to improve the certainty of this evidence.

27 28 **EEG Biofeedback/Neurofeedback**

29 The evidence in the clinical trials has not established clinical efficacy and effectiveness of
 30 EEG biofeedback for any indication. Studies include small patient populations and
 31 heterogeneous types of neurofeedback with short-term follow-ups (Lee et al., 2015;
 32 Angelakis, et al., 2007; Dohrmann, et al., 2007; McDonough-Means and Cohen, 2007).

33
 34 Renton et al. (2017) conducted a systematic review to evaluate the effectiveness of
 35 neurofeedback (NF) as a form of cognitive rehabilitation therapy for the treatment of stroke
 36 patients. Studies included subjects who were affected by a cognitive deficit following
 37 stroke (e.g., memory loss, loss of executive function, speech impairment). Seven studies
 38 met inclusion criteria including one randomized controlled trial, one non-randomized
 39 comparative trial, one case series and four case reports. Study designs and NF therapy and
 40 training protocols were heterogeneous. NF protocols were highly specific to each study
 41 (i.e., feedback location, number of sessions, training task involved, etc.). Most patients
 42 demonstrated moderate cognitive improvements in their respective pre-post NF outcome

1 measures including reported improvements in memory, mood, concentration, energy,
 2 reading and speech abilities, and/or motivation. The authors noted that it was unlikely that
 3 NF alone was responsible for the improved results. Because of the heterogeneity of the
 4 studies, meta-analysis could not be performed. Limitations of the studies include
 5 heterogeneous types of NF therapy; small patient populations; lack of a comparator;
 6 heterogeneity of the study designs; and poor quality of the studies. There is insufficient
 7 evidence to support NF therapy for cognitive rehabilitation of stroke patients.

8
 9 Reiter et al. (2016) conducted a systematic review of the literature to assess the effectiveness
 10 of neurofeedback (NF) for the treatment of posttraumatic stress disorder (PTSD). Five
 11 studies including one randomized controlled trial met inclusion criteria. Three studies used
 12 neurofeedback for combat-related PTSD. One study focused on children with insecure
 13 attachment and trauma-related PTSD and one study included participants with PTSD
 14 related to childhood abuse. NF approach included alpha wave, alpha/theta training,
 15 sensorimotor rhythm, or combination NF. Training sessions varied from 30 minutes to one
 16 hour and ranged from one single session to 30 sessions. Three studies reported a
 17 statistically significant reduction in targeted symptomatology while some measures failed
 18 to show any improvement. Limitations of the studies include limited number of studies;
 19 small patient populations (10–29); lack of female subjects; short-term follow-ups; lack of
 20 a comparator, and heterogeneity of treatment protocol and outcomes. Data are insufficient
 21 to support neurofeedback as an effective treatment option for PTSD. Additional research
 22 using well-designed randomized controlled trials with large patient populations is needed
 23 to establish which neurofeedback approach is clinically effective for PTSD.

24
 25 Luctkar-Flude et al. (2015) conducted a systematic review of the literature to evaluate the
 26 safety and effectiveness of neurofeedback of the management of fatigue and cognitive
 27 impairment. Seven randomized, three quasi-randomized and four nonrandomized trials
 28 (case series and retrospective reviews) met inclusion criteria. A study was eligible for
 29 inclusion if it included adult cancer survivors, individuals with other chronic health
 30 conditions or nonclinical populations seeking to decrease fatigue and/or enhance cognitive
 31 abilities. Two studies included cancer patients. Most of these studies reported positive
 32 results for at least one fatigue or cognitive outcome in a variety of clinical populations
 33 (traumatic brain injury, fibromyalgia, CNS problems) and nonclinical (college students,
 34 adults, elderly). Limitations of the studies included: small patient populations;
 35 heterogeneity of the types of neurofeedback, comparators, number of training sessions,
 36 outcome measures and diagnosis; subjects lost to follow-up; and short-term follow-ups
 37 Only four studies reported side effects or safety issues. Due to the limitations of the studies
 38 firm conclusions could not be made regarding the effectiveness of neurofeedback for
 39 fatigue and cognitive impairment including cancer patients.

40
 41 A Hayes (2003) review of 6 studies that met inclusion criteria concluded that “there is
 42 insufficient evidence from the available peer-reviewed literature to conclude that EEG

1 biofeedback therapy is effective for the treatment of disorders such as epilepsy, insomnia,
2 depression, mood disorders, posttraumatic stress disorder, alcoholism, drug addiction, or
3 menopausal symptoms”. Limitations of the studies included small patient populations,
4 inadequate or no controls, lack of randomization or comparison to conventional therapies,
5 and/or long-term follow-up, as well as inconsistent outcome measures and incomplete
6 reporting of data. Because of these methodological flaws, Hayes stated that “no definitive
7 conclusions regarding the efficacy of EEG biofeedback can be drawn.” In a subsequent
8 literature search (2008), Hayes’ conclusions had not changed. This report has been
9 archived.

10
11 Patel et al. (2020) evaluated the effectiveness and safety of neurofeedback (NFB) in
12 alleviating pain and pain-associated symptoms in chronic pain patients. Twenty-one
13 studies were included. Reduction in pain following NFB was reported by one high-quality
14 RCT, five of six low-quality RCT or NRCT and 13 of 14 case-series. Pain reduction
15 reported by studies ranged from 6% to 82%, with 10 studies reporting a clinically
16 significant reduction in pain of >30%. The overall effect size was medium (Cohen’s $d =$
17 0.76). Studies were highly heterogeneous. Improvements in depression, anxiety, fatigue
18 and sleep were also seen in some studies. Common side-effects included headache, nausea
19 and drowsiness. Authors concluded that neurofeedback is a safe and effective therapy with
20 promising but largely low-quality evidence supporting its use in chronic pain. Further high-
21 quality trials comparing different protocols is warranted to determine the most efficacious
22 way to deliver NFB.

23 Steingrimsson et al. (2020) aimed to assess whether EEG-NF, compared with sham NF,
24 other treatment, or no treatment, is effective for PTSD. Primary outcomes were self-harm,
25 PTSD symptoms, level of functioning and health-related quality of life. Four RCTs were
26 included (123 participants). Suicidal thoughts were significantly reduced after EEG-NF
27 compared with a waiting list in a small study. PTSD symptoms were assessed in all studies
28 with different instruments. Results were consistently in favor of EEG-NF with large effect
29 sizes. One study reported significantly improved level of executive functioning and one
30 study a reduction in use of psychotropic medication. Complications were scarcely reported.
31 Certainty of evidence was assessed as very low for the four assessed outcomes. Authors
32 concluded that based on four RCTs, with several study limitations and imprecision, it is
33 uncertain whether EEG-NF reduces suicidal thoughts, PTSD symptoms, medication use,
34 or improves function. Although all studies showed promising results, further studies are
35 needed to increase the certainty of evidence.

36
37 Hesam-Shariati et al. (2022) synthesized the evidence from randomized controlled trials
38 (RCTs) to evaluate the effect of EEG neurofeedback on chronic pain using random effects
39 meta-analyses. Additionally, they performed a narrative review to explore the results of
40 non-randomized studies. Ten RCTs and 13 non-randomized studies were included. The
41 primary meta-analysis on nine eligible RCTs indicated that although there is low
42 confidence, EEG neurofeedback may have a clinically meaningful effect on pain intensity

1 in short-term. Removing the studies with high risk of bias from the primary meta-analysis
2 resulted in moderate confidence that there remained a clinically meaningful effect on pain
3 intensity. Authors concluded that although there is promising evidence on the analgesic
4 effect of EEG neurofeedback, further studies with larger sample sizes and higher quality
5 of evidence are required.

6
7 Fernández-Alvarez et al. (2022) conducted a meta-analysis of studies extracted from
8 PubMed, Scopus, Web of Science and Embase with two objectives: A first group
9 comprising studies patients with major depressive disorder (MDD) and a second group
10 including studies targeting depressive symptomatology reduction in other mental or
11 medical conditions. In the first group of studies including patients with MDD, moderator
12 analyses indicate that treatment efficacy is only significant when accounting for
13 experimental design, in favor of randomized controlled trials (RCTs) in comparison to non
14 RCTs, whereas the type of neurofeedback, trial design, year of publication, number of
15 sessions, age, sex and quality of study did not influence treatment efficacy. In the second
16 group of studies, a small but significant effect between groups was found in favor of bio-
17 and neurofeedback against control groups. Moderator analyses revealed that treatment
18 efficacy was not moderated by any of the sociodemographic and clinical variables. Authors
19 concluded that heart rate variability (HRV) biofeedback and neurofeedback are associated
20 with a reduction in self-reported depression. Despite the fact that the field has still a large
21 room for improvement in terms of research quality, the results presented in this study
22 suggests that both modalities may become relevant complementary strategies for the
23 treatment of MDD and depressive symptomatology in the coming years.

24
25 Lima et al. (2022) reviewed the studies that investigated the effects of EEG neurofeedback
26 in subjects with alcohol use disorder (AUD) and it proposes to discuss this intervention as
27 a tool for reducing harm and risk in AUD. Most of the papers analyzed used the alpha/theta
28 protocol to reduce the 'hyperexcitation' of the nervous system. This protocol provides
29 relaxation, decreases anxiety or stress, prevents alcohol relapse, maintains abstinence, and
30 increases the feeling of well-being. EEG neurofeedback has important effects on AUD and
31 anxiety or stress. Studies reinforce the use of EEG neurofeedback as an alternative tool for
32 reducing harm and risk in AUD. EEG neurofeedback is an intervention to treat AUD,
33 specifically, to reduce harm and risk. However, more randomized studies are necessary to
34 consolidate and confirm the effectiveness of the technique despite these findings.

35
36 Pindi et al. (2022) provide 1) a state-of-art qualitative review of real-time functional MRI
37 (RT-fMRI-NF) studies aiming at alleviating clinical symptoms in a psychiatric population;
38 2) a quantitative evaluation (meta-analysis) of RT-fMRI-NF effectiveness on various
39 psychiatric disorders and 3) methodological suggestions for future studies. Thirty-one
40 clinical trials focusing on psychiatric disorders were included and categorized according to
41 standard diagnostic categories. Neurofeedback using (RT-fMRI-NF) is an innovative
42 technique that allows to voluntarily modulate a targeted brain response and its associated

1 behavior. Despite promising results in the current literature, its effectiveness on symptoms
2 management in psychiatric disorders is not yet clearly demonstrated. Among the 31
3 identified studies, 22 consisted of controlled trials, of which only eight showed significant
4 clinical improvement in the experimental vs. control group after the training. Nine studies
5 found an effect at follow-up on ADHD symptoms, emotion dysregulation, facial emotion
6 processing, depressive symptoms, hallucinations, psychotic symptoms, and specific
7 phobia. Within-group meta-analysis revealed large effects of the NF training on depressive
8 symptoms right after the training and at follow-up, as well as medium effects on anxiety
9 and emotion regulation. Between-group meta-analysis showed a medium effect non
10 depressive symptoms and a large effect on anxiety. However, the between-studies
11 heterogeneity is very high. The use of RT-fMRI-NF as a treatment for psychiatric
12 symptoms is promising, however, further double-blind, multicentric, randomized-
13 controlled trials are warranted to determine effectiveness.

14
15 Rahmani et al. (2022) evaluated the evidence related to the effectiveness of neurofeedback
16 treatment for children and adolescent with attention-deficit/hyperactivity disorder
17 (ADHD). A systematic review of randomized control trials (RCTs) was carried out across
18 multiple databases. the primary outcome measure was the most proximal ratings of ADHD
19 symptoms in subjects. Conner's Parent Rating Scale (CPRS), Conner's Teacher Rating
20 Scale (CTRS), and ADHD Rating Scale (ADHD-RS- are considered as primary outcomes.
21 Seventeen trials met inclusion criteria (including 1211 patients). Analysis showed that
22 there was no significant benefit of neurofeedback treatment compared with other
23 treatments or control. The results provide preliminary evidence that neurofeedback
24 treatment is not an efficacious clinical method for ADHD and suggest that more RTCs are
25 needed to compare common treatment.

26
27 Lin et al. (2022) sought to elucidate possible additive effects of electroencephalogram-
28 based neurofeedback (EEG-NF) on medications against the core symptoms of attention-
29 deficit/hyperactivity disorder (ADHD). The primary outcomes were changes in ADHD
30 symptoms (i.e., global, inattention, hyperactivity/impulsivity) assessed with validated
31 rating scales, while secondary outcome was all-cause discontinuation rate. Meta-analysis
32 of five RCTs involving 305 participants with a median follow-up of 12 weeks showed
33 additive effects of EEG-NF on medications from parents' observations against ADHD
34 global symptoms and inattention symptoms. However, additive effects failed to sustain six
35 months after EEG-NF intervention. Besides, there was no difference in improvement of
36 hyperactivity/impulsivity from parents' observation, attentional performance, and all-cause
37 discontinuation rate between the two groups. Authors state their results supported
38 additional benefits of combining EEG-NF with medications compared to medication alone
39 in treating global symptoms and symptoms of inattention in ADHD patients. However,
40 given a lack of evidence showing a correlation between underlying physiological changes
41 and small effect sizes in these preliminary results, further studies are warranted to support
42 our findings.

1 Patil et al. (2023) summarized the recent literature on electroencephalogram-
2 neurofeedback (EEG-NF) training for treating depression in a systematic review.
3 Conventional interventions to treat depression include long-term pharmacotherapy and
4 cognitive behavioral therapy. Electroencephalogram-neurofeedback (EEG-NF) training
5 has been suggested as a non-invasive option to treat depression with minimal side effects.
6 The 12 studies included in the final sample reported that despite several issues related to
7 EEG-NF practices, patients with depression showed significant cognitive, clinical, and
8 neural improvements following EEG-NF training. Given its low cost and the low risk of
9 side effects due to its non-invasive nature, authors suggest that EEG-NF is worth exploring
10 as an augmented tool for patients who already receive standard medications but remain
11 symptomatic, and that EEG-NF training may be an effective intervention tool that can be
12 utilized as a supplementary treatment for depression. Authors also suggest that
13 improvement of experimental designs and standards related to EEG-NF training practices
14 for treating depression are needed.

15
16 Askovic et al. (2023) conducted a systematic review and meta-analysis of ten clinical trials
17 to answer the question: how effective is NFB in addressing PTSD and other associated
18 symptoms across different trauma populations, and are these improvements related to
19 neurophysiological changes? Ten controlled studies were included; seven RCTs and three
20 NRSIs with a total number of participants $n = 293$ (128 male). Only RCTs were included
21 in the meta-analysis (215 participants; 88 male). All included studies showed an advantage
22 of NFB over control conditions in reducing symptoms of PTSD, with indications of
23 improvement in symptoms of anxiety and depression and related neurophysiological
24 changes. Meta-analysis of the pooled data shows a significant reduction in PTSD
25 symptoms post-treatment, and the mean remission rate was higher in the NFB group
26 (79.3%) compared to the control group (24.4%). However, the studies reviewed were
27 mostly small, with heterogeneous populations and varied quality. Authors concluded that
28 the effect of NFB on the symptoms of PTSD was moderate and mechanistic evidence
29 suggested that NFB leads to therapeutic changes in brain functioning. Future research
30 should focus on more rigorous methodological designs, expanded sample size and longer
31 follow-up.

32 33 **Home Biofeedback Devices**

34 Biofeedback should be performed in a clinical setting by trained professionals. The
35 evidence in the published peer-reviewed scientific literature does not support the
36 effectiveness of home electronic biofeedback devices. In some instances, the results of
37 clinical trials were limited due to the inability to monitor the use of home biofeedback used
38 by subjects in the trial. Peirce et al. (2013) conducted a randomized controlled trial ($n=120$)
39 to determine if home biofeedback alone would have better anal manometry results at three
40 months postpartum compared to pelvic floor exercises (PFEs) alone in women who
41 sustained a primary third-degree postpartum tear. The secondary outcome criterion was
42 improvement in continence scores. Subjects were randomized to home biofeedback ($n=30$)

1 (CombiStim XP, Neurotech®, Galway, Ireland) or conventional PFEs ($n=90$). At the 3-
 2 month follow-up, there was no significant difference in anal resting ($p=0.123$), squeeze
 3 pressure ($p=0.68$), and the Cleveland Clinic continence scores ($p=0.88$) between the groups.
 4 There were no significant differences in the Rockwood fecal incontinence quality of life
 5 scale score including: lifestyle ($p=0.29$), coping ($p=0.27$), depression ($p=0.89$) and
 6 embarrassment ($p=0.51$). Seven of the 30 biofeedback subjects reported poor adherence.
 7 Home biofeedback did not improve the clinical outcomes of this subpopulation of women.
 8 Limitations of the study include the small patient population and short-term follow-up.

9
 10 An earlier randomized controlled trial compared the use of anorectal manometry EMG
 11 biofeedback performed in a laboratory ($n=24$) to EMG biofeedback performed in the home
 12 ($n=12$) for children with chronic constipation who had failed conventional treatment. The
 13 outcomes indicated that no additional benefit was gained by the use of home biofeedback
 14 (Croffie et al., 2005). A randomized controlled trial by Aukee et al. (2004) reported that 11
 15 of 16 women who received 12 weeks of home EMG-assisted biofeedback (FemiScan™,
 16 MegaElectronics, Kuopio, Finland) avoided surgical intervention compared to ten of 19
 17 control subjects who did not use home biofeedback. In a 2002 decision memo regarding the
 18 use of home biofeedback for urinary incontinence, the Centers for Medicare and Medicaid
 19 (2002), stated that “the scientific evidence is not adequate to conclude that the use of home
 20 biofeedback devices for the treatment of urinary incontinence is clinically effective, and,
 21 therefore, is not reasonable and necessary for treating urinary incontinence or to improve
 22 the functioning of a malformed body member”.

23
 24 Cross et al. (2023) investigated and compared the efficacy of supervised Kegel exercises
 25 with bio-feedback on stress urinary incontinence (SUI) and pelvic floor muscle strength
 26 (PFMS) compared with unsupervised Kegel exercises. This was a matched-group quasi-
 27 experimental study of 29 female participants divided into two groups (supervised and non-
 28 supervised) and was conducted over 12 weeks. Baseline measurements of PFMS were
 29 undertaken by a women's health physiotherapist and a Kegel exercise regime bespoke
 30 designed for each participant. The supervised group visited the physiotherapist monthly for
 31 bio-feedback training (BT); the unsupervised group continued at home with their
 32 individualised Kegel exercises. Data were collected via a perineometer (Peritron™) and
 33 self-reporting responses to questionnaires. All participants received a final PFMS
 34 measurement on completion of the study. Results demonstrated that the overall
 35 Incontinence Severity index (ISI) score was significantly lower in the supervised group
 36 post-intervention. Wilcoxon signed-rank tests indicated that supervised Kegel exercises
 37 significantly reduced frequency ($p= 0.002$) and severity ($p= 0.020$) of overall ISI. Analysis
 38 of PFMS were not significantly different, despite an increase in maximum voluntary
 39 contraction or pelvic floor muscle strength (PFMS) ($p= 0.032$) in the supervised group. Of
 40 the questionnaires, results of Wilcoxon signed-rank tests indicated that "total bother" was
 41 significantly reduced ($p= 0.005$) in the supervised group. The correlation analysis between
 42 PFMS and ISI did not reveal any significant results. Authors concluded that the study

1 confirmed that supervised BT is more effective in reducing SUI than unsupervised Kegel
 2 exercises, and that this reduction in ISI score did not correlate with the improvement in
 3 PFMS.

4 **PRACTITIONER SCOPE AND TRAINING**

6 Practitioners should practice only in the areas in which they are competent based on their
 7 education, training, and experience. Levels of education, experience, and proficiency may
 8 vary among individual practitioners. It is ethically and legally incumbent on a practitioner
 9 to determine where they have the knowledge and skills necessary to perform such services
 10 and whether the services are within their scope of practice.

12 It is best practice for the practitioner to appropriately render services to a member only if
 13 they are trained, equally skilled, and adequately competent to deliver a service compared
 14 to others trained to perform the same procedure. If the service would be most competently
 15 delivered by another health care practitioner who has more skill and training, it would be
 16 best practice to refer the member to the more expert practitioner.

18 Best practice can be defined as a clinical, scientific, or professional technique, method, or
 19 process that is typically evidence-based and consensus driven and is recognized by a
 20 majority of professionals in a particular field as more effective at delivering a particular
 21 outcome than any other practice (Joint Commission International Accreditation Standards
 22 for Hospitals, 2017).

24 Depending on the practitioner’s scope of practice, training, and experience, a member’s
 25 condition and/or symptoms during examination or the course of treatment may indicate the
 26 need for referral to another practitioner or even emergency care. In such cases it is prudent
 27 for the practitioner to refer the member for appropriate co-management (e.g., to their
 28 primary care physician) or if immediate emergency care is warranted, to contact 911 as
 29 appropriate. See the *Managing Medical Emergencies (CPG 159 – S)* policy for
 30 information.

32 **REFERENCES**

33 American Cancer Society. Pain Control: A Non-medical treatments for pain. Retrieved on
 34 May 23, 2024 from <https://www.cancer.org/cancer/managing-cancer/side-effects/pain/non-medical-treatments-for-cancer-pain.html>

37 American Congress of Obstetricians and Gynecologists (ACOG). Committee on
 38 Gynecologic Practice. ACOG Committee Opinion: Number 673: Persistent vulvar pain.
 39 Sept 2016. Retrieved on March 22, 2024 from <https://www.acog.org/-/media/project/acog/acogorg/clinical/files/committee-opinion/articles/2016/09/persistent-vulvar-pain.pdf>

- 1 American Gastroenterological Association’s (AGA). (2013). Evaluation and management
2 of constipation. Retrieved on March 22, 2024 from [https://gastro.org/clinical-](https://gastro.org/clinical-guidance/evaluation-and-management-of-constipation/)
3 [guidance/evaluation-and-management-of-constipation/](https://gastro.org/clinical-guidance/evaluation-and-management-of-constipation/)
4
- 5 American Medical Association. (current year). Current Procedural Terminology (CPT)
6 Current year (rev. ed.). Chicago: AMA
7
- 8 American Medical Association (current year). HCPCS Level II. American Medical
9 Association
10
- 11 American Society of Anesthesiologists Task Force on Chronic Pain Management;
12 American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for
13 chronic pain management: an updated report by the American Society of
14 Anesthesiologists Task Force on Chronic Pain Management and the American Society
15 of Regional Anesthesia and Pain Medicine. *Anesthesiology*. 2010 Apr;112(4):810-33.
16 Retrieved on March 22, 2024 from
17 [https://pubs.asahq.org/anesthesiology/article/112/4/810/10691/Practice-Guidelines-](https://pubs.asahq.org/anesthesiology/article/112/4/810/10691/Practice-Guidelines-for-Chronic-Pain-ManagementAn)
18 [for-Chronic-Pain-ManagementAn](https://pubs.asahq.org/anesthesiology/article/112/4/810/10691/Practice-Guidelines-for-Chronic-Pain-ManagementAn)
19
- 20 American Urological Association. Surgical treatment of female stress urinary incontinence
21 (SUI): AUA/SUFU guideline. Retrieved on March 22, 2024 from
22 [https://www.auanet.org/guidelines-and-quality/guidelines/stress-urinary-](https://www.auanet.org/guidelines-and-quality/guidelines/stress-urinary-incontinence-(sui)-guideline)
23 [incontinence-\(sui\)-guideline](https://www.auanet.org/guidelines-and-quality/guidelines/stress-urinary-incontinence-(sui)-guideline)
24
- 25 Angelakis E, Stathopoulou S, Frymiare JL, Green DL, Lubar JF, Kounios J. EEG
26 neurofeedback: a brief overview and an example of peak alpha frequency training for
27 cognitive enhancement in the elderly. *Clin Neuropsychol*. 2007 Jan;21(1):110-29
28
- 29 Askovic M, Soh N, Elhindi J, Harris AWF. Neurofeedback for post-traumatic stress
30 disorder: systematic review and meta-analysis of clinical and neurophysiological
31 outcomes. *Eur J Psychotraumatol*. 2023;14(2):2257435
32
- 33 Astin JA, Beckner W, Soeken K, Hochberg MC, Berman B. Psychological interventions for
34 rheumatoid arthritis: a meta-analysis of randomized controlled trials. *Arthritis Rheum*.
35 2002;47(3):291-302
36
- 37 Aukee P, Immonen P, Laaksonen DE, Laippala P, Penttinen J, Airaksinen O. The effect of
38 home biofeedback training on stress incontinence. *Acta Obstet Gynecol Scand*. 2004
39 Oct;83(10):973-7
40
- 41 Babu AS, Mathew E, Danda D, Prakash H. Management of patients with fibromyalgia
42 using biofeedback: A randomized control trial. *Indian J Med Sci* 2007;61:455-61

- 1 Balbinot G, Joner Wiest M, Li G, et al. The use of surface EMG in neurorehabilitation
 2 following traumatic spinal cord injury: A scoping review. *Clin Neurophysiol.*
 3 2022;138:61-73. doi:10.1016/j.clinph.2022.02.028
 4
- 5 Barragán Loayza IM, Solà I, Juandó Prats C. Biofeedback for pain management during
 6 labour. *Cochrane Database of Systematic Reviews* 2011, Issue 6. Art. No.: CD006168
 7
- 8 Baumann FT, Reimer N, Gockeln T, et al. Supervised pelvic floor muscle exercise is more
 9 effective than unsupervised pelvic floor muscle exercise at improving urinary
 10 incontinence in prostate cancer patients following radical prostatectomy – a systematic
 11 review and meta-analysis. *Disabil Rehabil.* 2022 Sep;44(19):5374-5385. doi:
 12 10.1080/09638288.2021.1937717
 13
- 14 Berger MB, Patel DA, Miller JM, DeLancey JO, Fenner DE. Racial differences in self-
 15 reported healthcare seeking and treatment for urinary incontinence in community-
 16 dwelling women from the EPI study. *Neurourology and urodynamics.* 2011;30(8):1442–
 17 1447
 18
- 19 Bergeron S, Binik YM, Khalife S, Pagidas K, Glazer HI, Meana M, Amsel R. A randomized
 20 comparison of group cognitive-behavioral therapy, surface electromyographic
 21 biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar
 22 vestibulitis. *Pain.* 2001 Apr;91(3):297-306
 23
- 24 Brasileiro A, Gama G, Trigueiro L, Ribeiro T, Silva E, Galvão É, Lindquist A. Influence of
 25 visual and auditory biofeedback on partial body weight support treadmill training of
 26 individuals with chronic hemiparesis: a randomized controlled clinical trial. *Eur J Phys*
 27 *Rehabil Med.* 2015 Feb;51(1):49-58
 28
- 29 Brazzelli M, Griffiths P. Behavioural and cognitive interventions with or without other
 30 treatments for the management of faecal incontinence in children. *Cochrane Database*
 31 *Syst Rev.* 2006 Apr 19;(2):CD002240
 32
- 33 Brazzelli M, Griffiths PV, Cody JD, Tappin D. Behavioural and cognitive interventions
 34 with or without other treatments for the management of faecal incontinence in children.
 35 *Cochrane Database of Systematic Reviews* 2011, Issue 12. Art. No.: CD002240. DOI:
 36 10.1002/14651858.CD002240.pub4
 37
- 38 Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ, Fuchs FD,
 39 Hughes JW, Lackland DT, Staffileno BA, Townsend RR, Rajagopalan S; American
 40 Heart Association Professional Education Committee of the Council for High Blood
 41 Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on
 42 Epidemiology and Prevention, and Council on Nutrition, Physical Activity. Beyond

- 1 medications and diet: alternative approaches to lowering blood pressure: a scientific
 2 statement from the American Heart Association. *Hypertension*. 2013 Jun;61(6):1360-
 3 83
- 4
- 5 Brown HW, Dyer KY, Rogers RG. Management of Fecal Incontinence. *Obstet Gynecol*.
 6 2020 Oct;136(4):811-822. Doi: 10.1097/AOG.0000000000004054
- 7
- 8 Brown HW, Barnes HC, Lim A, Giles DL, McAchran SE. Better together:
 9 multidisciplinary approach improves adherence to pelvic floor physical therapy. *Int*
 10 *Urogynecol J*. 2020;31(5):887-893. doi:10.1007/s00192-019-04090-w
- 11
- 12 Brown O, Simon MA. Applying a Health Equity Lens to Urinary Incontinence. *Clin Obstet*
 13 *Gynecol*. 2021;64(2):266-275. doi:10.1097/GRF.0000000000000613
- 14
- 15 Brunnhuber K, Nash S, Meier DE, Weissman DE, Woodcock J. Putting evidence into
 16 practice: palliative care. *BMJ* 2008;1-88
- 17
- 18 Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, Varner RE, Lloyd
 19 LK. Behavioral training with and without biofeedback in the treatment of urge
 20 incontinence in older women: a randomized controlled trial. *JAMA*. 2002 Nov
 21 13;288(18):2293-9
- 22
- 23 Burgio KL, Goode PS, Urban DA, Umlauf MG, Locher JL, Bueschen A, Redden DT.
 24 Preoperative biofeedback assisted behavioral training to decrease post-prostatectomy
 25 incontinence: a randomized, controlled trial. *J Urol*. 2006 Jan;175(1):196-201;
 26 discussion 201
- 27
- 28 Burlacu A, Brinza C, Popa IV, Covic A, Floria M. Influencing Cardiovascular Outcomes
 29 through Heart Rate Variability Modulation: A Systematic Review. *Diagnostics (Basel)*.
 30 2021;11(12):2198. Published 2021 Nov 25
- 31
- 32 Bussadori SK, Motta LJ, Horliana ACRT, Santos EM, Martimbianco ALC. The Current
 33 Trend in Management of Bruxism and Chronic Pain: An Overview of Systematic
 34 Reviews. *J Pain Res*. 2020 Sep 30;13:2413-2421. Doi: 10.2147/JPR.S268114
- 35
- 36 Campo M, Zadro JR, Pappas E, Monticone M, Secci C, Scalzitti D, Findley JL, Graham
 37 PL. The effectiveness of biofeedback for improving pain, disability and work ability in
 38 adults with neck pain: A systematic review and meta-analysis. *Musculoskelet Sci Pract*.
 39 2021 Jan 8;52:102317
- 40
- 41 Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for
 42 Biofeedback Therapy (30.1). Retrieved on March 22, 2024 from

1 <https://www.cms.gov/medicare-coverage-database/details/ncd->
 2 [details.aspx?NCDId=41&ncdver=1&bc=AAAAGAAAAAA&](https://www.cms.gov/medicare-coverage-database/details/ncd-)

3
 4 Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for
 5 Biofeedback Therapy for the Treatment of Urinary Incontinence (30.1.1). Retrieved on
 6 March 22, 2024 from <https://www.cms.gov/medicare-coverage-database/details/ncd->
 7 [details.aspx?NCDId=42&ncdver=1&bc=AAAAGAAAAAA&](https://www.cms.gov/medicare-coverage-database/details/ncd-)

8
 9 Chiarioni G, Nardo A, Vantini I, Romito A, Whitehead WE. Biofeedback is superior to
 10 electrogalvanic stimulation and massage for treatment of levator ani syndrome.
 11 *Gastroenterology*. 2010 Apr;138(4):1321-9

12
 13 Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to
 14 laxatives for normal transit constipation due to pelvic floor dyssynergia.
 15 *Gastroenterology*. 2006 Mar;130(3):657-64

16
 17 Coben R, Linden M, Myers TE. Neurofeedback for autistic spectrum disorder: a review of
 18 the literature. *Appl Psychophysiol Biofeedback*. 2010 Mar;35(1):83- 105

19
 20 Crider A, Glaros AG, Gevirtz RN. Efficacy of biofeedback-based treatments for
 21 temporomandibular disorders. *Appl Psychophysiol Biofeedback*. 2005 Dec;30(4):333-
 22 45

23
 24 Croffie JM, Ammar MS, Pfefferkorn MD, Horn D, Klipsch A, Fitzgerald JF, Gupta SK,
 25 Molleston JP, Corkins MR. Assessment of the effectiveness of biofeedback in children
 26 with dyssynergic defecation and recalcitrant constipation/encopresis: does home
 27 biofeedback improve long-term outcomes. *Clin Pediatr (Phila)*. 2005 Jan-Feb;44(1):63-
 28 71

29
 30 Cross D, Waheed N, Krake M, Gahreman D. Effectiveness of supervised Kegel exercises
 31 using bio-feedback versus unsupervised Kegel exercises on stress urinary incontinence:
 32 a quasi-experimental study. *Int Urogynecol J*. 2023;34(4):913-920.

33
 34 Dannecker C, Wolf V, Raab R, Hepp H, Anthuber C. EMG-biofeedback assisted pelvic
 35 floor muscle training is an effective therapy of stress urinary or mixed incontinence: a
 36 7-year experience with 390 patients. *Arch Gynecol Obstet*. 2005 Dec;273(2):93-7

37
 38 Department of Veterans Affairs. VA/DOD clinical practice guideline for the management
 39 of stroke rehabilitation. 2019. Retrieved on March 22, 2024 from
 40 <https://www.healthquality.va.gov/guidelines/Rehab/stroke/index.asp>

- 1 Desantis DJ, Leonard MP, Preston MA, Barrowman NJ, Guerra LA. Effectiveness of
 2 biofeedback for dysfunctional elimination syndrome in pediatrics: a systematic review.
 3 J Pediatr Urol. 2011 Jun;7(3):342-8
 4
- 5 Doğan-Aslan M, Nakipoğlu-Yüzer GF, Doğan A, Karabay I, Özgirgin N. The effect of
 6 electromyographic biofeedback treatment in improving upper extremity functioning of
 7 patients with hemiplegic stroke. J Stroke Cerebrovasc Dis. 2012 Apr;21(3):187-92
 8
- 9 Dohrmann K, Weisz N, Schlee W, Hartmann T, Elbert T. Neurofeedback for treating
 10 tinnitus. Prog Brain Res. 2007;166:473-85
 11
- 12 Drużbicki M, Guzik A, Przysada G, Kwolek A, Brzozowska-Magoń A. Efficacy of gait
 13 training using a treadmill with and without visual biofeedback in patients after stroke:
 14 A randomized study. J Rehabil Med. 2015 May;47(5):419-25
 15
- 16 Ehrenborg C, Archenholtz B. Is surface EMG biofeedback an effective training method for
 17 persons with neck and shoulder complaints after whiplash-associated disorders
 18 concerning activities of daily living and pain – a randomized controlled trial. Clin
 19 Rehabil. 2010 Aug;24(8):715-26
 20
- 21 Elavally S, Ramamurthy MT, Subash J, Meleveedu R, Venkatasalu MR. Effect of nurse-
 22 led home-based biofeedback intervention on the blood pressure levels among patients
 23 with hypertension: Pretest-posttest study. J Family Med Prim Care. 2020 Sep
 24 30;9(9):4833-4840
 25
- 26 Enck P, van der Voort IR, Klosterhalfen S. Biofeedback therapy in fecal incontinence and
 27 constipation. Neurogastroenterol Motil. 2009 Jun 30
 28
- 29 Erickson BA, Schaeffer AJ, Van Le B. Chronic prostatitis. Clin Evid (Online). 2008 May
 30 22;2008. Pii: 1802
 31
- 32 Eslamian F, Jahanjoo F, Dolatkah N, Pishgahi A, Pirani A. Relative Effectiveness of
 33 Electroacupuncture and Biofeedback in the Treatment of Neck and Upper Back
 34 Myofascial Pain: A Randomized Clinical Trial. Arch Phys Med Rehabil. 2020
 35 May;101(5):770-780
 36
- 37 Fazeli MS1, Lin Y2, Nikoo N2, Jaggumantri S1, Collet JP1, Afshar K3. Biofeedback for
 38 nonneuropathic daytime voiding disorders in children: a systematic review and meta-
 39 analysis of randomized controlled trials. J Urol. 2015 Jan;193(1):274-9

- 1 Fernández-Alvarez J, Grassi M, Colombo D, et al. Efficacy of bio- and neurofeedback for
2 depression: a meta-analysis. *Psychol Med.* 2022;52(2):201-216.
3 doi:10.1017/S0033291721004396
4
- 5 Fitz FF, Resende AP, Stüpp L, Sartori MG, Girão MJ, Castro RA. Biofeedback for the
6 treatment of female pelvic floor muscle dysfunction: a systematic review and meta-
7 analysis. *Int Urogynecol J.* 2012 Mar 17
8
- 9 Forte ML, Andrade KE, Butler M, et al. Treatments for Fecal Incontinence [Internet].
10 Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Mar.
11 (Comparative Effectiveness Review, No. 165.) Available from:
12 <https://www.ncbi.nlm.nih.gov/books/NBK356097/>
13
- 14 Fournié C, Chouchou F, Dalleau G, Caderby T, Cabrera Q, Verkindt C. Heart rate
15 variability biofeedback in chronic disease management: A systematic review.
16 *Complement Ther Med.* 2021;60:102750
17
- 18 Fuchs T, Birbaumer N, Lutzenberger W, Gruzelier JH, Kaiser J. Neurofeedback treatment
19 for attention-deficit/hyperactivity disorder in children: a comparison with
20 methylphenidate. *Appl Psychophysiol Biofeedback.* 2003 Mar;28(1):1-12
21
- 22 Fullerton ME, Mwesigwa PJ, Tandel MD, Kwan L, Grisales T, Tarnay CM. Comparison
23 of Pelvic Floor Physical Therapy Attendance Based on Referring Provider Specialty.
24 *Female Pelvic Med Reconstr Surg.* 2022;28(1):57-63.
25 doi:10.1097/SPV.0000000000001061
26
- 27 Giggins OM, Persson UM, Caulfield B. Biofeedback in rehabilitation. *J Neuroeng Rehabil.*
28 2013 Jun 18;10:60
29
- 30 Gladstein J. Headache. *Med Clin North Am.* 2006 Mar;90(2):275-90
31
- 32 Glasscoe CA, Quittner AL. Psychological interventions for people with cystic fibrosis and
33 their families. *Cochrane Database Syst Rev.* 2008 Jul 16;(3):CD003148
34
- 35 Glatcke KE, Tummala SV, Chhabra A. Anterior Cruciate Ligament Reconstruction
36 Recovery and Rehabilitation: A Systematic Review. *J Bone Joint Surg Am.*
37 2022;104(8):739-754. Doi:10.2106/JBJS.21.00688
38
- 39 Goldenberg JZ, Brignall M, Hamilton M, Beardsley J, Batson RD, Hawrelak J,
40 Lichtenstein B, Johnston BC. Biofeedback for treatment of irritable bowel syndrome.
41 *Cochrane Database Syst Rev.* 2019 Nov 12;2019(11):CD012530

- 1 Greenhalgh J, Dickson R, Dundar Y. The effects of biofeedback for the treatment of
 2 essential hypertension: a systematic review. *Health Technol Assess.* 2009
 3 Oct;13(46):1-104
 4
- 5 Haefner HK, Collins ME, Davis GD, Edwards L, Foster DC, Hartmann ED, Kaufman RH,
 6 Lynch PJ, Margesson LJ, Moyal-Barracco M, Piper CK, Reed BD, Stewart EG,
 7 Wilkinson EJ. The vulvodynia guideline. *J Low Genit Tract Dis.* 2005 Jan;9(1):40-51
 8
- 9 Hagen S, Elders A, Stratton S, Sergenson N, Bugge C, Dean S, Hay-Smith J, Kilonzo M,
 10 Dimitrova M, Abdel-Fattah M, Agur W, Booth J, Glazener C, Guerrero K, McDonald
 11 A, Norrie J, Williams LR, McClurg D. Effectiveness of pelvic floor muscle training
 12 with and without electromyographic biofeedback for urinary incontinence in women:
 13 multicentre randomised controlled trial. *BMJ.* 2020 Oct 14;371:m3719
 14
- 15 Hagen S, Bugge C, Dean SG, et al. Basic versus biofeedback-mediated intensive pelvic
 16 floor muscle training for women with urinary incontinence: the OPAL RCT. *Health
 17 Technol Assess.* 2020;24(70):1-144. doi:10.3310/hta24700
 18
- 19 Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services
 20 Task Force: a review of the process. *Am J Prev Med.* 2001; 20:21–35
 21
- 22 Hayes Inc. Hayes Medical Technology Directory™. Electroencephalogram (EEG)
 23 biofeedback therapy. Lansdale, PA: HAYES Inc.; Apr 11, 2003; reviewed 2008
 24
- 25 Hayes Inc. Hayes Update Search™. Electroencephalogram (EEG) Biofeedback Therapy.
 26 Lansdale, PA: Mar 13, 2008
 27
- 28 Hayes Inc. Search and Summary. Biofeedback for Spastic Torticollis. Lansdale, PA: Sept
 29 15, 2016
 30
- 31 Hayes Inc. Search and Summary. Biofeedback for the treatment of dysfunctional voiding
 32 in children. Lansdale, PA: Jun 16, 2016
 33
- 34 Heinrich H, Gevensleben H, Strehl U. Annotation: neurofeedback – train your brain to train
 35 behaviour. *J Child Psychol Psychiatry.* 2007 Jan;48(1):3-16
 36
- 37 Henschke N, Ostelo RWJG, van Tulder MW, Vlaeyen JWS, Morley S, Assendelft WJJ,
 38 Main CJ. Behavioural treatment for chronic low-back pain. *Cochrane Database of
 39 Systematic Reviews* 2010, Issue 7. Art. No.: CD002014.
 40 DOI:10.1002/14651858.CD002014.pub3

- 1 Herbison GP, Dean N. Weighted vaginal cones for urinary incontinence. *Cochrane*
2 *Database of Systematic Reviews* 2002, Issue 1. Art. No.: CD002114. DOI:
3 10.1002/14651858.CD002114
4
- 5 Herderschee R, Hay-Smith EJC, Herbison GP, Roovers JP, Heineman MJ. Feedback or
6 biofeedback to augment pelvic floor muscle training for urinary incontinence in
7 women. *Cochrane Database of Systematic Reviews* 2011, Issue 7. Art. No.: CD009252.
8 DOI:10.1002/14651858.CD009252
9
- 10 Hesam-Shariati N, Chang WJ, Wewege MA, et al. The analgesic effect of
11 electroencephalographic neurofeedback for people with chronic pain: A systematic
12 review and meta-analysis. *Eur J Neurol.* 2022;29(3):921-936. doi:10.1111/ene.15189
13
- 14 Heymen S, Jones KR, Scarlett Y, Whitehead WE. Biofeedback treatment of constipation:
15 a critical review. *Dis Colon Rectum.* 2003 Sep;46(9):1208-17
16
- 17 Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized,
18 controlled trial shows biofeedback to be superior to alternative treatments for patients
19 with pelvic floor dyssynergia-type constipation. *Dis Colon Rectum.* 2007
20 Apr;50(4):428-41
21
- 22 Hite M, Curran T. Biofeedback for Pelvic Floor Disorders. *Clin Colon Rectal Surg.* 2021
23 Jan;34(1):56-61. Doi: 10.1055/s-0040-1714287
24
- 25 Hjelland IE, Svebak S, Berstad A, Flatabø G, Hausken T. Breathing exercises with vagal
26 biofeedback may benefit patients with functional dyspepsia. *Scand J Gastroenterol.* 2007
27 Sep;42(9):1054-62
28
- 29 Höder A, Stenbeck J, Fernando M, Lange E. Pelvic floor muscle training with biofeedback
30 or feedback from a physiotherapist for urinary and anal incontinence after childbirth -
31 a systematic review. *BMC Womens Health.* 2023 Nov 18;23(1):618.
32
- 33 Holroyd KA, Mauskop A. Complementary and alternative treatments. *Neurology.* 2003
34 Apr 8;60(7)
35
- 36 Holroyd-Leduc JM, Tannenbaum C, Thorpe KE, Straus SE. What type of urinary
37 incontinence does this woman have? *JAMA.* 2008 Mar 26;299(12):1446-56
38
- 39 Holtmann M, Stadler C. Electroencephalographic biofeedback for the treatment of
40 attention-deficit hyperactivity disorder in childhood and adolescence. *Expert Rev*
41 *Neurother.* 2006 Apr;6(4):533-40

- 1 Huffman J, Sakonju A. Chapter 19 – Neurology. Differential diagnosis of recurrent or
2 chronic headaches. In: Johns Hopkins: The Harriet Lane Handbook: A Manual for
3 Pediatric House Officers, 17th ed. Philadelphia. Mosby's, 2005
4
- 5 Hunter KF, Moore KN, Cody DJ, Glazener CM. Conservative management for
6 postprostatectomy urinary incontinence. *Cochrane Database Syst Rev.*
7 2004;(2):CD001843
8
- 9 Ilnyckyj A, Fachnie E, Tougas G. A randomized-controlled trial comparing an educational
10 intervention alone vs education and biofeedback in the management of faecal
11 incontinence in women. *Neurogastroenterol Motil.* 2005 Feb;17(1):58-63
12
- 13 Italian Society of Colorectal Surgery (SICCR), Pucciani F, Altomare DF, Dodi G, Falletto
14 E, Frasson A, Giani I, Martellucci J, Naldini G, Piloni V, Sciaudone G; Italian
15 Association of Hospital Gastroenterologists (AIGO), Bove A, Bocchini R, Bellini M,
16 Alduini P, Battaglia E, Galeazzi F, Rossitti P, Usai Satta P. Diagnosis and treatment of
17 faecal incontinence: Consensus statement of the Italian Society of Colorectal Surgery
18 and the Italian Association of Hospital Gastroenterologists. *Dig Liver Dis.* 2015
19 Aug;47(8):628-45
20
- 21 Jacobsen LV, Jørgensen CS, Kaas Sørensen KM, Enemark L, Rittig S, Kamperis K. The
22 efficacy of physiotherapeutic intervention with biofeedback assisted pelvic floor muscle
23 training in children with dysfunctional voiding. *J Pediatr Urol.* 2021;17(6):793.e1-
24 793.e6
25
- 26 Johnson EE, Mamoulakis C, Stoniute A, Omar MI, Sinha S. Conservative interventions for
27 managing urinary incontinence after prostate surgery. *Cochrane Database Syst Rev.*
28 2023;4(4):CD014799. Published 2023 Apr 18. doi:10.1002/14651858.CD014799.pub2
29
- 30 Joint Commission International. (2020). Joint Commission International Accreditation
31 Standards for Hospitals (7th ed.): Joint Commission Resources
32
- 33 Jokubauskas L, Baltrušaitytė A. Efficacy of biofeedback therapy on sleep bruxism: A
34 systematic review and meta-analysis. *J Oral Rehabil.* 2018 Jun;45(6):485-495. Doi:
35 10.1111/joor.12628. Epub 2018 Apr 11
36
- 37 Jones L, Othman M, Dowswell T, Alfirevic Z, Gates S, Newburn M, Jordan S, Lavender T,
38 Neilson JP. Pain management for women in labour: an overview of systematic reviews.
39 *Cochrane Database of Systematic Reviews* 2012, Issue 3. Art. No.: CD009234. DOI:
40 10.1002/14651858.CD009234.pub2

- 1 Karaborklu Argut S, Celik D, Yasacı Z. Effectiveness of therapeutic electromyographic
2 biofeedback after orthopedic knee surgeries: a systematic review. *Disabil Rehabil.*
3 2021 Jan 8:1-9
4
- 5 Karjalainen K, Malmivaara A, van Tulder M, Roine R, Jauhiainen M, Hurri H, et al.
6 Biopsychosocial rehabilitation for upper limb repetitive strain injuries in working age
7 adults. *The Cochrane Review*. In: *The Cochrane Library*, Issue 3, 2000. Update Dec
8 2004. Chichester, UK: John Wiley & sons, Ltd.; 2004. Oxford: Update software
9
- 10 Karmody CS. Alternative therapies in the management of headache and facial pain.
11 *Otolaryngol Clin N Am.* 2003;36:1221–30
12
- 13 Kaushik R, Kaushik RM, Mahajan SK, Rajesh V. Biofeedback assisted diaphragmatic
14 breathing and systematic relaxation versus propranolol in long term prophylaxis of
15 migraine. *Complement Ther Med.* 2005 Sep;13(3):165-74
16
- 17 Kiresuk TJ, Trachtenberg A. Alternative and complementary health practices. Sadock BJ,
18 Sadock VA, editors. In: *Kaplan & Sadock's Comprehensive textbook of psychiatry.*
19 PA: Lippincott Williams & Wilkins. 2005
20
- 21 Klijn AJ, Uiterwaal CS, Vijverberg MA, Winkler PL, Dik P, de Jong TP. Home
22 uroflowmetry biofeedback in behavioral training for dysfunctional voiding in school-
23 age children: a randomized controlled study. *J Urol.* 2006 Jun;175(6):2263-8;
24 discussion 2268
25
- 26 Koh CE, Young CJ, Young JM, Solomon MJ. Systematic review of randomized controlled
27 trials of the effectiveness of biofeedback for pelvic floor dysfunction. *Br J Surg.* 2008
28 Sep;95(9):1079-87
29
- 30 Kuo LJ, Lin YC, Lai CH, Lin YK, Huang YS, Hu CC, Chen SC. Improvement of fecal
31 incontinence and quality of life by electrical stimulation and biofeedback for patients
32 with low rectal cancer after intersphincteric resection. *Arch Phys Med Rehabil.* 2015
33 Aug;96(8):1442-7
34
- 35 Lacima G, Pera M, Amador A, Escaramís G, Piqué JM. Long-term results of biofeedback
36 treatment for faecal incontinence: a comparative study with untreated controls.
37 *Colorectal Dis.* 2009 Apr 10
38
- 39 Ladi-Seyedian S, Kajbafzadeh AM, Sharifi-Rad L, Shadgan B, Fan E. Management of non-
40 neuropathic underactive bladder in children with voiding dysfunction by animated
41 biofeedback: a randomized clinical trial. *Urology.* 2015 Jan;85(1):205-10. Doi:
42 10.1016/j.urology.2014.09.025

- 1 Lee YS, Bae SH, Lee SH, Kim KY. Neurofeedback training improves the dual-task
2 performance ability in stroke patients. *Tohoku J Exp Med.* 2015;236(1):81-8
3
- 4 Leonardo K, Seno DH, Mirza H, Afriansyah A. Biofeedback-assisted pelvic floor muscle
5 training and pelvic electrical stimulation in women with overactive bladder: A
6 systematic review and meta-analysis of randomized controlled trials. *Neurourol*
7 *Urodyn.* 2022;41(6):1258-1269. Doi:10.1002/nau.24984
8
- 9 Li H, Guo C, Gao J, Yao H. Effectiveness of Biofeedback Therapy in Patients with Bowel
10 Dysfunction Following Rectal Cancer Surgery: A Systemic Review with Meta-
11 Analysis. *Ther Clin Risk Manag.* 2022;18:71-93. Published 2022 Feb 2
12
- 13 Li RY, Chen KY, Wang XR, Yu Q, Xu L. Comparison of Different Rehabilitation
14 Techniques of Traditional Chinese and Western Medicine in the Treatment of Motor
15 Dysfunction After Stroke Based on Frequency Method: A Network Meta-analysis. *Am*
16 *J Phys Med Rehabil.* 2023;102(6):504-512.
17
- 18 Lima KHM, Gomes JS, Tucci AM. Electroencephalographic neurofeedback as a tool for
19 reducing harm and risk associated with alcohol use disorder: A critical review. *Drug*
20 *Alcohol Rev.* 2022;41(3):594-602. doi:10.1111/dar.13387
21
- 22 Lin FL, Sun CK, Cheng YS, et al. Additive effects of EEG neurofeedback on medications
23 for ADHD: a systematic review and meta-analysis. *Sci Rep.* 2022;12(1):20401.
24 Published 2022 Nov 27.
25
- 26 Lirio-Romero C, Torres-Lacomba M, Gómez-Blanco A, Acero-Cortés A, Retana-Garrido
27 A, de la Villa-Polo P, Sánchez-Sánchez B. Electromyographic biofeedback improves
28 upper extremity function: a randomized, single-blinded, controlled trial. *Physiotherapy.*
29 2021 Mar;110:54-62
30
- 31 Litvinas, I. Ch 31 – stroke (cerebrovascular disease). In: *Rakel: Integrative Medicine, 2nd*
32 *ed.* Philadelphia: Saunders Elsevier, 2007
33
- 34 Luo, L. , Li, L. , Chen, X. and Zeng, F. (2021) Research Progress on Compliance of Pelvic
35 Floor Muscle Training in Patients with Urinary Incontinence. *Open Journal of Urology,*
36 11, 187-199. doi: 10.4236/oju.2021.116017
37
- 38 Luctkar-Flude M, Groll D. A Systematic Review of the Safety and Effect of Neurofeedback
39 on Fatigue and Cognition. *Integr Cancer Ther.* 2015 Jul;14(4):318-40

- 1 Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine
2 in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis.
3 *Rheumatology (Oxford)*. 2009 Jul;48(7):791-5
4
- 5 Malik K, Dua A. Biofeedback. 2020 Dec 5. In: StatPearls [Internet]. Treasure Island (FL):
6 StatPearls Publishing; 2021 Jan
7
- 8 Martino Cinnera A, Morone G, Bisirri A, Lucenti T, Rotundo M, Monaci S, Berton C,
9 Paoluzzi M, Iosa M, Ciancarelli I. Headaches treatment with EMG biofeedback: a
10 focused systematic review and meta-analysis. *Eur J Phys Rehabil Med*. 2023
11 Dec;59(6):697-705
12
- 13 McConaghy JR. Headache in primary care. *Prim Care*. 2007 Mar;34(1):83-97
14
- 15 McDonough-Means SI, Cohen MW. Chapter 11. Attention deficit disorder. In: Rakel:
16 *Integrative Medicine*, 2nd ed. Philadelphia: Saunders Elsevier, 2007
17
- 18 McGinnis RA, McGrady A, Cox SA, Grower-Dowling KA. Biofeedback-assisted
19 relaxation in type 2 diabetes. *Diabetes Care*. 2005 Sep;28(9):2145-9
20
- 21 McGrady A. The effects of biofeedback in diabetes and essential hypertension. *Cleve Clin*
22 *J Med*. 2010 Jul;77 Suppl 3:S68-71
23
- 24 McKee MG, Moravec CS. Biofeedback in the treatment of heart failure. *Cleve Clin J Med*.
25 2010 Jul;77 Suppl 3:S56-9
26
- 27 Medlicott MS, Harris SR. A systematic review of the effectiveness of exercise, manual
28 therapy, electrotherapy, relaxation training, and biofeedback in the management of
29 temporomandibular disorder. *Phys Ther*. 2006 Jul;86(7):955-73
30
- 31 Middaugh SJ, Haythornthwaite JA, Thompson B, Hill R, Brown KM, Freedman RR,
32 Attanasio V, Jacob RG, Scheier M, Smith EA. The Raynaud’s Treatment Study:
33 biofeedback protocols and acquisition of temperature biofeedback skills. *Appl*
34 *Psychophysiol Biofeedback*. 2001 Dec;26(4):251-78
35
- 36 Minardi D, d’Anzeo G, Parri G, Polito M Jr, Piergallina M, El Asmar Z, Marchetti M,
37 Muzzonigro G. The role of uroflowmetry biofeedback and biofeedback training of the
38 pelvic floor muscles in the treatment of recurrent urinary tract infections in women with
39 dysfunctional voiding: a randomized controlled prospective study. *Urology*. 2010
40 Jun;75(6):1299-304

- 1 Moen MD, Noone MB, Vassallo BJ, Elser DM; Urogynecology Network. Pelvic floor
2 muscle function in women presenting with pelvic floor disorders. *Int Urogynecol J*
3 *Pelvic Floor Dysfunct.* 2009;20(7):843-846. doi:10.1007/s00192-009-0853-6
4
- 5 Moore D, Young CJ. A systematic review and meta-analysis of biofeedback therapy for
6 dyssynergic defaecation in adults. *Tech Coloproctol.* 2020 Sep;24(9):909-918
7
- 8 Morrill MMD, Lukacz ESMD, Lawrence JMMPHS, Nager CWMD, Contreras RMS,
9 Luber KMMD. Seeking healthcare for pelvic floor disorders: a population-based study.
10 *American journal of obstetrics and gynecology.* 2007;197(1):86.e81–86.e86
11
- 12 Nagai Y, Goldstein LH, Fenwick PB, Trimble MR. Clinical efficacy of galvanic skin
13 response biofeedback training in reducing seizures in adult epilepsy: a preliminary
14 randomized controlled study. *Epilepsy Behav.* 2004 Apr;5(2):216-23
15
- 16 Nakao M, Yano E, Nomura S, Kuboki T. Blood pressure-lowering effects of biofeedback
17 treatment in hypertension: a meta-analysis of randomized controlled trials. *Hypertens*
18 *Res.* 2003 Jan;26(1):37-46
19
- 20 Narayanan SP, Bharucha AE. A Practical Guide to Biofeedback Therapy for Pelvic Floor
21 Disorders. *Curr Gastroenterol Rep.* 2019 Apr 23;21(5):21
22
- 23 Nascimento RP, Falsetta ML, Maurer T, Sarmiento ACA, Gonçalves AK. Efficacy of
24 Physiotherapy for Treating Vulvodynia: A Systematic Review. *J Low Genit Tract Dis.*
25 2024 Jan 1;28(1):54-63.
26
- 27 National Center for Complementary and Alternative Medicine (NCCAM). Terms related
28 to complementary and integrative health. Retrieved on March 25, 2024 from
29 <http://nccam.nih.gov/health/providers/camterms.htm>
30
- 31 National Institute for Health and Clinical Excellence (NICE). Clinical guideline 61. Irritable
32 bowel syndrome in adults. Diagnosis and management. Feb 2008; updated Apr 2017.
33 Retrieved on March 25, 2024 from <http://guidance.nice.org.uk/CG61>
34
- 35 National Institute for Health and Clinical Excellence (NICE). Clinical guideline 99.
36 Constipation in children and young people: diagnosis and management. May 26, 2010;
37 updated 2017. Retrieved on March 25, 2024 from
38 <https://www.nice.org.uk/guidance/cg99>
39
- 40 National Institute for Health and Clinical Excellence (NICE). Clinical guideline 137.
41 Epilepsies in children, young people and adults. April 2022. Retrieved on March 25,
42 2024 from <https://www.nice.org.uk/guidance/ng217>

- 1 National Institute for Health and Clinical Excellence (NICE). Clinical guideline 49. Faecal
2 incontinence in adults: management. Jun 2007. Retrieved on March 25, 2024 from
3 <http://guidance.nice.org.uk/CG49/>
4
- 5 National Institute for Health and Clinical Excellence (NICE). Clinical guideline 123.
6 Urinary incontinence and pelvic organ prolapse in women: management. Jun 2019.
7 Retrieved on March 25, 2024 from <https://www.nice.org.uk/guidance/ng123>
8
- 9 NCCN Clinical Practice Guidelines in Oncology®. ©2019 National Comprehensive Cancer
10 Network, Inc. Adult Cancer Pain. Retrieved on March 25, 2024 from
11 <https://www.nccn.org/framework/>
12
- 13 Neblett R, Mayer TG, Brede E, Gatchel RJ. Correcting abnormal flexion-relaxation in
14 chronic lumbar pain: responsiveness to a new biofeedback training protocol. *Clin J Pain*.
15 2010 Jun;26(5):403-9
16
- 17 Nelson LA. The role of biofeedback in stroke rehabilitation: past and future directions. *Top*
18 *Stroke Rehabil*. 2007 Jul-Aug;14(4):59-66
19
- 20 Nestoriuc Y, Martin A. Efficacy of biofeedback for migraine: a meta-analysis. *Pain*. 2007
21 Mar;128(1-2):111-27
22
- 23 Nestoriuc Y, Rief W, Martin A. Meta-analysis of biofeedback for tension-type headache:
24 Efficacy, specificity, and treatment moderators. *J Consult Clin Psychol*. 2008
25 Jun;76(3):379-96
26
- 27 Norton C, Chelvanayagam S, Wilson-Barnett J, Redfern S, Kamm MA. Randomized
28 controlled trial of biofeedback for fecal incontinence. *Gastroenterol*. 2003
29 Nov;125(5):1320-9
30
- 31 Norton C, Cody JD. Biofeedback and/or sphincter exercises for the treatment of faecal
32 incontinence in adults. *Cochrane Database of Systematic Reviews* 2012, Issue 7. Art.
33 No.: CD002111
34
- 35 Norton C, Cody JD, Hosker G. Biofeedback and/or sphincter exercises for the treatment of
36 faecal incontinence in adults. *Cochrane Database Syst Rev*. 2006 Jul 19;3:CD002111
37
- 38 Norton C, Hosker G, Brazzelli M. Biofeedback and/or sphincter exercises for the treatment
39 of faecal incontinence in adults. *The Cochrane Review*. In: *The Cochrane Library*, Issue
40 2, 2000. Update Jan 31, 2002. Chichester, UK:John Wiley & sons, Ltd.; 2002

- 1 Ostelo RW, van Tulder MW , Vlaeyen JW, Linton SJ, Morley SJ, Assendelft WJ.
 2 Behavioural treatment for chronic low-back pain. The Cochrane Review. In: The
 3 Cochrane Library, Issue 2, 2000. Update Oct 1, 2003. Chichester, UK:John Wiley &
 4 sons, Ltd.; 2005
 5
- 6 Paquette IM, Varma M, Ternent C, Melton-Meaux G, Rafferty JF, Feingold D, Steele SR.
 7 The American Society of Colon and Rectal Surgeons' Clinical Practice Guideline for
 8 the Evaluation and Management of Constipation. *Dis Colon Rectum*. 2016
 9 Jun;59(6):479-92. doi: 10.1097/DCR.0000000000000599. PMID: 27145304
 10
- 11 Paquette IM, Varma MG, Kaiser AM, Steele SR, Rafferty JF. The American Society of
 12 Colon and Rectal Surgeons' Clinical Practice Guideline for the Treatment of Fecal
 13 Incontinence. *Dis Colon Rectum*. 2015 Jul;58(7):623-36. doi:
 14 10.1097/DCR.0000000000000397. PMID: 26200676
 15
- 16 Patcharatrakul T, Rao SS. Update on the Pathophysiology and Management of Anorectal
 17 Disorders. *Gut Liver*. 2018 Jul; 12(4): 375–384
 18
- 19 Patel K, Sutherland H, Henshaw J, Taylor JR, Brown CA, Casson AJ, Trujillo-Barreton
 20 NJ, Jones AKP, Sivan M. Effects of neurofeedback in the management of chronic pain:
 21 A systematic review and meta-analysis of clinical trials. *Eur J Pain*. 2020
 22 Sep;24(8):1440-1457
 23
- 24 Patil AU, Lin C, Lee SH, et al. Review of EEG-based neurofeedback as a therapeutic
 25 intervention to treat depression. *Psychiatry Res Neuroimaging*. 2023;329:111591
 26
- 27 Payne, CK. Chapter 63 – Conservative management of urinary incontinence: behavioral
 28 and pelvic floor therapy, urethral and pelvic devices. *Pelvic floor rehabilitation*. In;
 29 Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. *Wein: Campbell-
 30 Walsh Urology*, 9th ed. Orlando, Fl. WB Sanders Company. 2007
 31
- 32 Peirce C1, Murphy C, Fitzpatrick M, Cassidy M, Daly L, O’Connell PR, O’Herlihy C.
 33 Randomised controlled trial comparing early home biofeedback physiotherapy with
 34 pelvic floor exercises for the treatment of third-degree tears (EBAPT Trial). *BJOG*.
 35 2013 Sep;120(10):1240-7
 36
- 37 Pindi P, Houenou J, Piguet C, Favre P. Real-time fMRI neurofeedback as a new treatment
 38 for psychiatric disorders: A meta-analysis. *Prog Neuropsychopharmacol Biol
 39 Psychiatry*. 2022;119:110605. doi:10.1016/j.pnpbp.2022.110605

- 1 Pollock A, Baer G, Pomeroy V, Langhorne P. Physiotherapy treatment approaches for the
2 recovery of postural control and lower limb function following stroke. *Cochrane*
3 *Database Syst Rev.* 2007 Jan 24;(1):CD001920
4
- 5 Pollock A, Baer G, Pomeroy V, Langhorne P. Physiotherapy treatment approaches for the
6 recovery of postural control and lower limb function following stroke. *Cochrane*
7 *Database Syst Rev.* 2003;(2):CD001920
8
- 9 Pollock A, Baer G, Campbell P, et al. Physical rehabilitation approaches for the recovery
10 of function and mobility following stroke. *Cochrane Database Syst Rev.*
11 2014;2014(4):CD001920. Published 2014 Apr 22.
12 doi:10.1002/14651858.CD001920.pub3
13
- 14 Porena M, Costantini E, Rociola W, Mearini E. Biofeedback successfully cures detrusor-
15 sphincter dyssynergia in pediatric patients. *J Urol.* 2000 Jun;163(6):1927-31
16
- 17 Porta Roda O, Díaz López MA, Vara Paniagua J, Simó González M, Díaz Bellido P,
18 Espinós Gómez JJ. Adherence to pelvic floor muscle training with or without vaginal
19 spheres in women with urinary incontinence: a secondary analysis from a randomized
20 trial. *Int Urogynecol J.* 2016;27(8):1185-1191. doi:10.1007/s00192-015-2941-0
21
- 22 Pun MY, Leung PH, Chan TC, Pang C, Chan KH, Kannan P. The effectiveness of
23 physiotherapy interventions on fecal incontinence and quality of life following
24 colorectal surgery: a systematic review and meta-analysis of randomized controlled
25 trials. *Support Care Cancer.* 2024 Jan 13;32(2):103
26
- 27 Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and
28 Chronic Low Back Pain: A Clinical Practice Guideline From the American College of
29 Physicians. *Ann Intern Med.* 2017;166(7):514-530. doi:10.7326/M16-2367
30
- 31 Qi W, Zhou Y, Zhong M, et al. The effect of biofeedback treatment for children with non-
32 neurogenic voiding dysfunction: A systematic review and meta-analysis [published
33 online ahead of print, 2022 Feb 22]. *Neurourol Urodyn.* 2022;10.1002/nau.24886
34
- 35 Rahmani E, Mahvelati A, Alizadeh A, et al. Is neurofeedback effective in children with
36 ADHD? A systematic review and meta-analysis. *Neurocase.* 2022;28(1):84-95.
37 doi:10.1080/13554794.2022.2027456
38
- 39 Ramaratnam S, Baker GA, Goldstein LH. Psychological treatments for epilepsy. *Cochrane*
40 *Database Syst Rev.* 2008, Issue 3. Art. No.: CD002029. DOI:
41 10.1002/14651858.CD002029.pub3

- 1 Rao SS, Benninga MA, Bharucha AE, Chiarioni G, Di Lorenzo C, Whitehead WE. ANMS-
2 ESNM position paper and consensus guidelines on biofeedback therapy for anorectal
3 disorders. *Neurogastroenterol Motil.* 2015 May;27(5):594-609
4
- 5 Rao SS, Bharucha AE, Chiarioni G, Felt-Bersma R, Knowles C, Malcolm A, Wald A.
6 Functional Anorectal Disorders. *Gastroenterology.* 2016 Mar 25. pii: S0016-
7 5085(16)00175-X
8
- 9 Rao SS, Patcharatrakul T. Diagnosis and Treatment of Dyssynergic Defecation. *J*
10 *Neurogastroenterol Motil.* 2016 Jul; 22(3): 423–435
11
- 12 Rao SS, Seaton K, Miller M, Brown K, Nygaard I, Stumbo P, Zimmerman B, Schulze K.
13 Randomized controlled trial of biofeedback, sham feedback, and standard therapy for
14 dyssynergic defecation. *Clin Gastroenterol Hepatol.* 2007 Mar;5(3):331-8
15
- 16 Raynaud’s Treatment Study Investigators. Comparison of sustained-release nifedipine and
17 temperature biofeedback for treatment of primary Raynaud phenomenon: Results from
18 a randomized clinical trial with 1-year follow-up. *Arch Intern Med.* 2000 Apr
19 24;160(8):1101-8. doi:10.1001/archinte.160.8.1101
20
- 21 Reiner R. Integrating a portable biofeedback device into clinical practice for patients with
22 anxiety disorders: results of a pilot study. *Appl Psychophysiol Biofeedback.* 2008
23 Mar;33(1):55-61
24
- 25 Reiter K, Andersen SB, Carlsson J. Neurofeedback Treatment and Posttraumatic Stress
26 Disorder: Effectiveness of Neurofeedback on Posttraumatic Stress Disorder and the
27 Optimal Choice of Protocol. *J Nerv Ment Dis.* 2016 Feb;204(2):69-77
28
- 29 Remes-Troche JM, Coss-Adame E, García-Zermeño KR, Gómez-Escudero O, Amieva-
30 Balmori M, Gómez-Castaños PC, Charúa-Guindic L, Icaza-Chávez ME, López-
31 Colombo A, Morel-Cerda EC, Pérez Y López N, Rodríguez-Leal MC, Salgado-Nesme
32 N, Sánchez-Avila MT, Valdovinos-García LR, Vergara-Fernández O, Villar-Chávez
33 AS. The Mexican consensus on fecal incontinence. *Rev Gastroenterol Mex (Engl Ed).*
34 2023 Oct-Dec;88(4):404-428.
35
- 36 Reneau M. Heart Rate Variability Biofeedback to Treat Fibromyalgia: An Integrative
37 Literature Review. *Pain Manag Nurs.* 2020 Jun;21(3):225-232. doi:
38 10.1016/j.pmn.2019.08.001
39
- 40 Renton T, Tibbles A, Topolovec-Vranic J. Neurofeedback as a form of cognitive
41 rehabilitation therapy following stroke: A systematic review. *PLoS One.* 2017 May
42 16;12(5):e0177290

- 1 Richards R, van den Noort JC, Dekker J, Harlaar J. Gait Retraining With Real-Time
2 Biofeedback to Reduce Knee Adduction Moment: Systematic Review of Effects and
3 Methods Used. *Arch Phys Med Rehabil.* 2017 Jan;98(1):137-150
4
- 5 Sadeghi A, Akbarpour E, Majidirad F, et al. Dyssynergic Defecation: A Comprehensive
6 Review on Diagnosis and Management. *Turk J Gastroenterol.* 2023;34(3):182-195.
7 doi:10.5152/tjg.2023.22148
8
- 9 Sam E, Cinislioglu AE, Yilmazel FK, Demirdogen SO, Yilmaz AH, Karabulut I. Is
10 biofeedback-assisted pelvic floor muscle training superior to pelvic floor muscle
11 training alone in the treatment of dysfunctional voiding in women? A prospective
12 randomized study. *Int Braz J Urol.* 2022;48(3):501-511. Doi:10.1590/S1677-
13 5538.IBJU.2021.0687
14
- 15 Skardoon GR, Khera AJ, Emmanuel AV, Burgell RE. Review article: dyssynergic
16 defaecation and biofeedback therapy in the pathophysiology and management of
17 functional constipation. *Aliment Pharmacol Ther.* 2017 Aug;46(4):410-423
18
- 19 Shamliyan TA, Kane RL, Wyman J, Wilt TJ. Systematic review: randomized, controlled
20 trials of nonsurgical treatments for urinary incontinence in women. *Ann Intern Med.*
21 2008 Mar 18;148(6):459-73. Epub 2008 Feb 11
22
- 23 Shannon MB, Genereux M, Brincat C, et al. Attendance at Prescribed Pelvic Floor Physical
24 Therapy in a Diverse, Urban Urogynecology Population. *PM R.* 2018;10(6):601-606.
25 doi:10.1016/j.pmrj.2017.11.008
26
- 27 Shannon MB, Adams W, Fitzgerald CM, Mueller ER, Brubaker L, Brincat C. Does Patient
28 Education Augment Pelvic Floor Physical Therapy Preparedness and Attendance? A
29 Randomized Controlled Trial. *Female Pelvic Med Reconstr Surg.* 2018;24(2):155-160.
30 doi:10.1097/SPV.0000000000000516
31
- 32 Shedden Mora MC1, Weber D, Neff A, Rief W. Biofeedback-based cognitive-behavioral
33 treatment compared with occlusal splint for temporomandibular disorder: a randomized
34 controlled trial. *Clin J Pain*
35
- 36 Sokhadze TM, Cannon RL, Trudeau DL. EEG biofeedback as a treatment for substance
37 use disorders: review, rating of efficacy, and recommendations for further research.
38 *Appl Psychophysiol Biofeedback.* 2008 Mar;33(1):1-28
39
- 40 Spencer J, Wolf SL, Kesar TM. Biofeedback for Post-stroke Gait Retraining: A Review of
41 Current Evidence and Future Research Directions in the Context of Emerging
42 Technologies. *Front Neurol.* 2021;12:637199

- 1 Stanton R, Ada L, Dean CM, Preston E. Biofeedback improves activities of the lower limb
2 after stroke: a systematic review. *J Physiother.* 2011;57(3):145-55
3
- 4 Stanton R, Ada L, Dean CM, Preston E. Biofeedback improves performance in lower limb
5 activities more than usual therapy in people following stroke: a systematic review. *J*
6 *Physiother.* 2017 Jan;63(1):11-16
7
- 8 Steingrimsson S, Bilonic G, Ekelund AC, et al. Electroencephalography-based
9 neurofeedback as treatment for post-traumatic stress disorder: A systematic review and
10 meta-analysis. *Eur Psychiatry.* 2020;63(1):e7. Published 2020 Jan 31.
11 doi:10.1192/j.eurpsy.2019.7
12
- 13 Sterman MB. Biofeedback in the treatment of epilepsy. *Cleve Clin J Med.* 2010 Jul;77
14 Suppl 3:S60-7
15
- 16 Stockdale CK, Lawson HW. 2013 Vulvodynia Guideline update. *J Low Genit Tract Dis.*
17 2014 Apr;18(2):93-10
18
- 19 Tabbers MM, DiLorenzo C, Berger MY, Faure C, Langendam MW, Nurko S, Staiano A,
20 Vandenplas Y, Benninga MA; European Society for Pediatric Gastroenterology,
21 Hepatology, and Nutrition; North American Society for Pediatric Gastroenterology.
22 Evaluation and treatment of functional constipation in infants and children: evidence-
23 based recommendations from ESPGHAN and NASPGHAN. *J Pediatr Gastroenterol*
24 *Nutr.* 2014 Feb;58(2):258-74. doi: 10.1097/MPG.0000000000000266. PMID:
25 24345831
26
- 27 Tate JJ, Milner CE. Real-time kinematic, temporospatial, and kinetic biofeedback during
28 gait retraining in patients: a systematic review. *Phys Ther.* 2010 Aug;90(8):1123-34
29
- 30 Tiryaki P, Çelik D, Bilsel K, Erşen A. Effectiveness of Exercises With Electromyographic
31 Biofeedback in Conservative Treatment of Massive Rotator Cuff Tears: A Randomized
32 Controlled Study. *Am J Phys Med Rehabil.* 2023;102(5):419-426
33
- 34 Todhunter-Brown A, Hazelton C, Campbell P, Elders A, Hagen S, McClurg D.
35 Conservative interventions for treating urinary incontinence in women: an Overview
36 of Cochrane systematic reviews. *Cochrane Database Syst Rev.* 2022;9(9):CD012337.
37 Published 2022 Sep 2. doi:10.1002/14651858.CD012337.pub2
38
- 39 U.S. Food and Drug Administration (FDA). Title 21—food and drugs. Biofeedback device.
40 Retrieved on March 25, 2024 from [https://www.ecfr.gov/current/title-21/chapter-](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-882/subpart-F/section-882.5050)
41 [I/subchapter-H/part-882/subpart-F/section-882.5050](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-882/subpart-F/section-882.5050)

- 1 Vasudeva S, Claggett AL, Tietjen GE, McGrady AV. Biofeedback-assisted relaxation in
2 migraine headache: relationship to cerebral blood flow velocity in the middle cerebral
3 artery. *Headache*. 2003;43:245-50
4
- 5 Vitton V, Damon H, Benezech A, Bouchard D, Brardjanian S, Brochard C, Coffin B,
6 Fathallah N, Higuero T, Jouët P, Leroi AM, Luciano L, Meurette G, Piche T, Ropert
7 A, Sabate JM, Siproudhis L; SNFCP CONSTI Study Group. Clinical practice
8 guidelines from the French National Society of Coloproctology in treating chronic
9 constipation. *Eur J Gastroenterol Hepatol*. 2018 Apr;30(4):357-363
10
- 11 Vonthein R, Heimerl T, Schwandner T, Ziegler A. Electrical stimulation and biofeedback
12 for the treatment of fecal incontinence: a systematic review. *Int J Colorectal Dis*. 2013
13 Nov;28(11):1567-77
14
- 15 Wagner B, Steiner M, Huber DFX, Crevenna R. The effect of biofeedback interventions
16 on pain, overall symptoms, quality of life and physiological parameters in patients with
17 pelvic pain : A systematic review. *Wien Klin Wochenschr*. 2022;134(Suppl 1):11-48
18
- 19 Wahbeh H, Elsas SM, Oken BS. Mind-body interventions: applications in neurology.
20 *Neurology*. 2008 Jun 10;70(24):2321-8
21
- 22 Wang LF1, Long H, Deng M, Xu H, Fang J, Fan Y, Bai D, Han XL. Biofeedback treatment
23 for sleep bruxism: a systematic review. *Sleep Breath*. 2014 May;18(2):235-42
24
- 25 Wang R, Zhang S, Zhang J, Tong Q, Ye X, Wang K, Li J. Electromyographic biofeedback
26 therapy for improving limb function after stroke: A systematic review and meta-
27 analysis. *PLoS One*. 2024 Jan 11;19(1):e0289572
28
- 29 Wasielewski NJ, Parker TM, Kotsko KM. Evaluation of electromyographic biofeedback
30 for the quadriceps femoris: a systematic review. *J Athl Train*. 2011;46(5):543-54
31
- 32 Wattchow KA, McDonnell MN, Hillier SL. Rehabilitation Interventions for Upper Limb
33 Function in the First Four Weeks Following Stroke: A Systematic Review and Meta-
34 Analysis of the Evidence. *Arch Phys Med Rehabil*. 2018 Feb;99(2):367-382
35
- 36 Weber W, Newmark S. Complementary and alternative medical therapies for attention-
37 deficit/hyperactivity disorder and autism. *Pediatr Clin North Am*. 2007 Dec;54(6):983-
38 1006; xii
39
- 40 Wegh CAM, Baaleman DF, Tabbers MM, Smidt H, Benninga MA. Non-pharmacological
41 Treatment for Children With Functional Constipation: A Systematic Review and Meta-

- 1 analysis [published online ahead of print, 2021 Sep 15]. *J Pediatr.* 2021;S0022-
2 3476(21)00883-0
- 3
- 4 Weise C, Heinecke K, Rief W. Biofeedback-based behavioral treatment for chronic
5 tinnitus: results of a randomized controlled trial. *J Consult Clin Psychol.* 2008
6 Dec;76(6):1046-57
- 7
- 8 Whitehead WE, Chaussade S, Corazziari E, Kumar D: Report of an international workshop
9 on management of constipation. *Gastroenterol Int* 4:99–113, 1991
- 10
- 11 Woodford H, Price C. EMG biofeedback for the recovery of motor function after stroke.
12 *Cochrane Database Syst Rev.* 2007 Apr 18;(2):CD004585
- 13
- 14 Wu JM, Hundley AF, Fulton RG, Myers ER. Forecasting the prevalence of pelvic floor
15 disorders in U.S. Women: 2010 to 2050. *Obstet Gynecol.* 2009;114(6):1278-1283.
16 doi:10.1097/AOG.0b013e3181c2ce96
- 17
- 18 Wu X, Zheng X, Yi X, Lai P, Lan Y. Electromyographic Biofeedback for Stress Urinary
19 Incontinence or Pelvic Floor Dysfunction in Women: A Systematic Review and Meta-
20 Analysis. *Adv Ther.* 2021;38(8):4163-4177
- 21
- 22 Xie YJ, Wang S, Gong QJ, et al. Effects of electromyography biofeedback for patients after
23 knee surgery: A systematic review and meta-analysis. *J Biomech.* 2021;120:110386
- 24
- 25 Yagci S, Kibar Y, Akay O, Kilic S, Erdemir F, Gok F, Dayanc M. The effect of biofeedback
26 treatment on voiding and urodynamic parameters in children with voiding dysfunction.
27 *J Urol.* 2005 Nov;174(5):1994-7; discussion 1997-8
- 28
- 29 Yang JM, Ye H, Long Y, et al. Effect of pelvic floor muscle training on urinary
30 incontinence after radical prostatectomy: An umbrella review of meta-analysis and
31 systematic review. *Clin Rehabil.* 2023;37(4):494-515
- 32
- 33 Yao L, Sadeghirad B, Li M, Li J, Wang Q, Crandon HN, Martin G, Morgan R, Florez ID,
34 Hunskar BS, Wells J, Moradi S, Zhu Y, Ahmed MM, Gao Y, Cao L, Yang K, Tian J,
35 Li J, Zhong L, Couban RJ, Guyatt GH, Agoritsas T, Busse JW. Management of chronic
36 pain secondary to temporomandibular disorders: a systematic review and network
37 meta-analysis of randomised trials. *BMJ.* 2023 Dec 15;383:e076226
- 38
- 39 Yilmaz OO, Senocak O, Sahin E, Baydar M, Gulbahar S, Bircan C, Alper S. Efficacy of
40 EMG-biofeedback in knee osteoarthritis. *Rheumatol Int.* 2010 May;30(7):887-92

- 1 Yucha CB, Clark L, Smith M, Uris P, LaFleur B, Duval S. The effect of biofeedback in
2 hypertension. *Applied Nursing Research*. 2001;14(1):29-35
3
- 4 Zhang Y, Hou S, Qi Z, Wu S, Zhu K, Wang W. Non-pharmacological and nonsurgical
5 interventions in male urinary incontinence: A scoping review. *J Clin Nurs*. 2023;32(17-
6 18):6196-6211
7
- 8 Zijlstra A, Mancini M, Chiari L, Zijlstra W. Biofeedback for training balance and mobility
9 tasks in older populations: a systematic review. *J Neuroeng Rehabil*. 2010 Dec 9;7:58